Certain Chemicals, Compositions, and Methods
Patent Information
- Application Number
- JP2023534417
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-02
- Filing Date
- 2021-12-01
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2041-12-01
AI Technical Summary
Existing treatments for diseases mediated by aberrant Raf kinase activity, such as cancer, lack effective small molecule inhibitors that can stabilize and regulate kinase activity, leading to uncontrolled cell proliferation and differentiation.
Development of crystalline forms of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, specifically Crystalline Form I and Crystalline Form II, which are characterized by distinct X-ray powder diffraction patterns, thermal properties, and stability under various conditions, providing a potent and selective Raf kinase inhibitor.
The crystalline forms of the compound demonstrate enhanced stability and selectivity in inhibiting Raf kinases, offering therapeutic benefits in treating a wide range of cancers by modulating kinase activity and regulating cell proliferation.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] (Reference to related applications) This application claims the interests of U.S. Provisional Patent Application No. 63 / 120,588, filed on 2 December 2020, which is incorporated herein by reference in its entirety.
[0002] This specification describes compounds that are Raf kinase inhibitors, methods for producing such compounds, pharmaceutical compositions and agents comprising such compounds, and methods for using such compounds in which modulation of Raf kinase activity would be beneficial in the treatment of a disease, disorder, or disability. Technical Background
[0003] There are at least 400 enzymes identified as protein kinases. These enzymes catalyze the phosphorylation of target protein substrates. Phosphorylation is typically the transfer of a phosphate group from ATP to a protein substrate. The specific structure in the target substrate to which the phosphate is transferred is a tyrosine, serine, or threonine residue. Because these amino acid residues are the target structures for phosphate transfer, these protein kinase enzymes are commonly called tyrosine kinases or serine / threonine kinases.
[0004] Phosphorylation reactions, as well as phosphatase reactions at tyrosine, serine, and threonine residues, are involved in countless cellular processes (usually mediated by cell receptors) that underlie diverse responses to intracellular signals, the regulation of cellular function, and the activation or deactivation of cellular processes. Protein kinase cascades are often involved in intracellular signaling and are essential for the realization of these cellular processes. Due to their ubiquitous presence in these processes, protein kinases may be found as integral parts of the plasma membrane, as cytoplasmic enzymes, or often localized in the nucleus as components of enzyme complexes. In many cases, these protein kinases are essential elements of enzyme-structural protein complexes, determining where and when cellular processes occur within the cell.
[0005] Therefore, the identification of small, effective compounds that specifically inhibit signaling and cell proliferation by modulating the activity of tyrosine and serine / threonine kinases in order to regulate and control abnormal or inappropriate cell proliferation, differentiation, or metabolism is desirable. Specifically, the identification of compounds that specifically inhibit the function of kinases essential for cancer-related processes would be beneficial. [Overview of the Initiative]
[0006] In one embodiment, the present disclosure relates to crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide) (compound A)
[0007] [ka] The present invention provides a pharmaceutically acceptable solvate or hydrate thereof.
[0008] In some embodiments, the crystal morphology is crystal morphology I. In some embodiments, crystal morphology I is (a) X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, including peaks at 8.7±0.2°²-θ, 21.6±0.2°²-θ, and 24.4±0.2°²-θ. (b) A substantially the same X-ray powder diffraction pattern as shown in Figure 1, (c) Differential scanning calorimetry (DSC) thermogram including endothermic temperatures in the range of approximately 180-190°C. (d) Differential scanning calorimetry (DSC) thermogram including endothermic heating with an onset of approximately 184°C and a peak of approximately 187°C. (e) A differential scanning calorimetry (DSC) thermogram substantially identical to that shown in Figure 2, (f) A thermogravimetric analysis (TGA) thermogram that is substantially the same as the one shown in Figure 3. (g) XRPD that remains unchanged after being stored at 40°C and 75% relative humidity (RH) for 6 months. XRPD that remains unchanged after being stored for 6 months at (h)25°C and relative humidity (RH)60%, or (i) characterized by combinations thereof.
[0009] In some embodiments, crystalline form I is characterized by an X-ray powder diffraction pattern that includes peaks at 8.7±0.2°²-θ, 21.6±0.2°²-θ, and 24.4±0.2°²-θ, as measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 17.5±0.2°²-θ, 14.6±0.2°²-θ, and 19.3±0.2°²-θ, as measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least five peaks selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, includes peaks at 8.7±0.1°2-θ, 21.6±0.1°2-θ, 24.4±0.1°2-θ, 17.5±0.1°2-θ, 14.6±0.1°2-θ, 19.3±0.1°2-θ, 23.1±0.1°2-θ, 16.0±0.1°2-θ, and 25.7±0.1°2-θ. In some embodiments, crystalline morphology I features an X-ray powder diffraction pattern substantially identical to that shown in Figure 1.
[0010] In some embodiments, crystalline morphology I is characterized by a differential scanning calorimetry (DSC) thermogram that includes endothermic activity in the range of approximately 180–190°C. In some embodiments, crystalline morphology I is characterized by a differential scanning calorimetry (DSC) thermogram that includes endothermic activity with an onset of approximately 184°C and a peak of approximately 190°C. In some embodiments, crystalline morphology I is characterized by a differential scanning calorimetry (DSC) thermogram that is substantially the same as that shown in Figure 2.
[0011] In some embodiments, crystalline morphology I is characterized by a thermogravimetric analysis (TGA) thermogram substantially identical to that shown in Figure 3.
[0012] In some embodiments, the crystal morphology is crystal morphology II. In some embodiments, crystal morphology II is (a) X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, including peaks at 11.8 ± 0.2°²-θ, 8.6 ± 0.2°²-θ, and 15.1 ± 0.2°²-θ. (b) A substantially the same X-ray powder diffraction pattern as shown in Figure 4, (c)i) Endothermic temperature in the range of approximately 135-145°C, ii) Heat generation in the range of approximately 143-145°C, iii) Endothermic temperature range of 155~145℃ and Differential scanning calorimetry (DSC) thermograms, (d)i) Endothermic with an onset of approximately 138°C and a peak of approximately 143°C, ii) Exothermic reaction with an onset of approximately 146°C and a peak of approximately 148°C, iii) Endothermic with an onset of approximately 158°C and a peak of approximately 160°C Differential scanning calorimetry (DSC) thermograms, (e) A differential scanning calorimetry (DSC) thermogram substantially identical to that shown in Figure 5, or (f) combinations of those, It is characterized by the following.
[0013] In some embodiments, crystalline form II is characterized by an X-ray powder diffraction pattern that includes peaks at 11.8±0.2°²-θ, 8.6±0.2°²-θ, and 15.1±0.2°²-θ, as measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 17.2±0.2°²-θ, 9.3±0.2°²-θ, and 23.6±0.2°²-θ, as measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further comprises at least one peak selected from 21.5±0.2° 2-θ, 22.2±0.2° 2-θ, and 14.3±0.2° 2-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern comprises at least five peaks selected from 11.8±0.2° 2-θ, 8.6±0.2° 2-θ, 15.1±0.2° 2-θ, 17.2±0.2° 2-θ, 9.3±0.2° 2-θ, 23.6±0.2° 2-θ, 21.5±0.2° 2-θ, 22.2±0.2° 2-θ, and 14.3±0.2° 2-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern comprises peaks at 11.8±0.1° 2-θ, 8.6±0.1° 2-θ, 15.1±0.1° 2-θ, 17.2±0.1° 2-θ, 9.3±0.1° 2-θ, 23.6±0.1° 2-θ, 21.5±0.1° 2-θ, 22.2±0.1° 2-θ, and 14.3±0.1° 2-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, crystalline form II is characterized by an X-ray powder diffraction pattern substantially the same as that shown in FIG. 4.
[0014] In some embodiments, crystalline form II i) an endotherm in the range of about 135 to 145 °C, and ii) an exotherm in the range of about 143 to 145 °C, and iii) an endotherm in the range of 155 to 165 °C characterized by a differential scanning calorimetry (DSC) thermogram.
[0015] In some embodiments, crystalline form II i) an endotherm having an onset at about 138 °C and a peak at about 143 °C, and ii) an exotherm having an onset at about 146 °C and a peak at about 148 °C, and iii) an endotherm having an onset at about 158 °C and a peak at about 160 °C characterized by a differential scanning calorimetry (DSC) thermogram.
[0016] In some embodiments, crystalline morphology II is characterized by a differential scanning calorimetry (DSC) thermogram substantially identical to that shown in Figure 5.
[0017] In another embodiment, the disclosure provides a pharmaceutical composition comprising crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide and at least one pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is formulated for administration to mammals by oral administration. In some embodiments, the pharmaceutical composition is in the form of a solid pharmaceutical composition. In some embodiments, the pharmaceutical composition is in the form of a tablet, pill, or capsule.
[0018] In another aspect, the Disclosure provides a packaged pharmaceutical composition comprising the pharmaceutical composition described herein and instructions for using the composition to treat a subject suffering from cancer.
[0019] In another embodiment, the present disclosure is a method for treating a neoplasm of an object requiring treatment, comprising administering to a patient a therapeutically effective dose of crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide, or any of the pharmaceutical compositions described herein. In some embodiments, the neoplasm is cancer. In some embodiments, cancers include colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma, vascular sarcoma, endosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovial tumor, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, thyroid cancer, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, liver cancer, cholangiocarcinoma, choriocarcinoma, seminocarcinoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular cancer, lung cancer, and small cell lung cancer. These include non-small cell lung cancer, bladder cancer, epithelial cancer, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal glandoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), leukemia, acute lymphoblastic leukemia, and acute myeloid leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia), chronic leukemia (chronic myeloid (granulocytic) leukemia and chronic lymphocytic leukemia), as well as polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström macroglobulinemia, or heavy chain disease. In some embodiments, the cancer is melanoma. In some embodiments, the melanoma is unresectable or metastatic melanoma. In some embodiments, the cancer is non-small cell lung cancer. In some embodiments, the cancer is colon cancer. In some embodiments, the cancer is thyroid cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the neoplasm is a benign tumor. In some embodiments, the tumor is a craniopharyngioma.
[0020] In another aspect, the present disclosure provides a method for preparing crystalline form I of crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide, the method being (a) To obtain the solution, the steps include dissolving N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide in a solvent, (b) The step of crystallizing the solution obtained in step (a) in order to obtain crystalline form I of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide.
[0021] In some embodiments, the solvent in step (a) includes ethyl acetate, DCM, ethanol, or isopropanol. In some embodiments, the solvent in step (a) includes ethyl acetate. In some embodiments, step (a) is carried out at a temperature of about 60–90°C. In some embodiments, step (a) is carried out at a temperature of about 75–80°C. In some embodiments, step (a) is carried out for about 1–3 hours. In some embodiments, step (a) is carried out for about 2 hours.
[0022] In some embodiments, step (b) includes cooling the solution obtained in step (a) to room temperature. In some embodiments, step (b) includes cooling the solution obtained in step (a) to a temperature of 20-25°C. In some embodiments, the method further includes filtering the crystallized solution obtained in step (b) to obtain crystalline form I. In some embodiments, the method further includes drying the obtained crystalline form I. In some embodiments, the drying step is carried out under vacuum at a temperature of about 40-50°C.
[0023] In another aspect, the present disclosure provides a method for preparing crystalline form II of crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide, the method being (a) To obtain the first solution, the steps include dissolving N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide in a solvent, (b) The step of adding water to the first solution obtained in step (a) in order to form a mixture, (c) A step of separating the mixture obtained in step (b) into an organic phase and an aqueous phase, (d) A step of isolating solids from the organic phase, (e) In order to obtain a second solution, the solid obtained in step (d) is dissolved in a second solvent, (f) The process includes the step of crystallizing the second solution obtained in step (a) in order to obtain crystalline form II of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide.
[0024] In some embodiments, the solvent in step (a) includes ethyl acetate, DCM, ethanol, or isopropanol. In some embodiments, the amount of water added in step (b) is such that the weight ratio of water to the solvent added in step (a) is approximately 1:1 to 1:10. In some embodiments, the amount of water added in step (b) is such that the weight ratio of water to the solvent added in step (a) is approximately 1:2 to 1:4.
[0025] In some embodiments, step (d) includes a step of concentrating the organic phase. In some embodiments, the concentrating step is carried out under vacuum at a temperature of about 40–50°C. In some embodiments, the second solvent in step (e) includes ethyl acetate, DCM, ethanol, or isopropanol. In some embodiments, the second solvent in step (e) is ethyl acetate. In some embodiments, step (f) includes a step of cooling the second solution obtained in step (a) to a temperature of 10–20°C. In some embodiments, the solution is maintained at a temperature of about 10–20°C for about 3–5 hours.
[0026] In some embodiments, the method further includes filtering the crystallization solution obtained in step (f) to obtain crystalline form II. In some embodiments, the method further includes drying the obtained crystalline form II. In some embodiments, the drying step is carried out under vacuum at a temperature of about 50-60°C.
[0027] Reference All publications, patents, and patent applications referenced herein are incorporated herein by reference in whole to the same extent that each individual publication, patent, or patent application is shown to be specifically and individually referenced. [Brief explanation of the drawing]
[0028] Novel features of the present invention are described in particular in the appended claims. A better understanding of the features and advantages of this disclosure will be obtained by referring to the following detailed description, which includes exemplary embodiments in which the principles of this disclosure are utilized, and to the accompanying drawings. [Figure 1] The X-ray powder diffraction (XRPD) pattern for crystalline form I of compound A is shown. [Figure 2] A differential scanning calorimetry (DSC) thermogram for crystalline form I of compound A is shown. [Figure 3] The thermogravimetric analysis (TGA) thermogram for crystalline form I of compound A is shown. [Figure 4] The X-ray powder diffraction (XRPD) pattern for crystalline form II of compound A is shown. [Figure 5] A differential scanning calorimetry (DSC) thermogram of crystalline form II of compound A is shown. [Figure 6] The X-ray powder diffraction (XRPD) pattern of crystalline form I of compound A, stored for 6 months at 40°C and 75% relative humidity (RH), is shown. [Figure 7] The differential scanning calorimetry (DSC) thermogram of crystalline form I of compound A, stored for 6 months at 40°C and 75% relative humidity (RH), is shown. [Figure 8] The X-ray powder diffraction (XRPD) pattern of crystalline form I of compound A, stored for 6 months at 25°C and 60% relative humidity (RH), is shown. [Figure 9] The differential scanning calorimetry (DSC) thermogram of crystalline form I of compound A, stored for 6 months at 25°C and 60% relative humidity (RH), is shown. Detailed Invention
[0029] Small molecule inhibitors are often initially evaluated for their activity when dissolved in solution, but their properties in the solid state, such as polymorphisms, are also important. Polymorphisms of active pharmaceutical ingredients (APIs), such as kinase inhibitors, can have a variety of physical properties, including melting point, apparent solubility, dissolution rate, optical and mechanical properties, vapor pressure, and density. These properties can directly affect the ability to process or manufacture the API and formulation. Furthermore, differences in these properties can, and often, lead to different pharmacokinetic profiles for different polymorphic forms of a drug. Therefore, polymorphism is often a crucial factor in routinely testing the "identity" of formulations from various products. For example, polymorphism is evaluated for many drugs worth millions, even billions of dollars, such as warfarin sodium, famotidine, and ranitidine. Polymorphism can affect the quality, safety, and / or efficacy of formulations such as kinase inhibitors. Thus, the need for polymorphisms of kinase inhibitors remains. This disclosure addresses this need and also provides related benefits.
[0030] Compound A As used herein, compound A refers to N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, which has the chemical structure shown below.
[0031] [ka]
[0032] Compound A is a potent and selective Raf kinase inhibitor. Raf kinase inhibitors are useful in treating various diseases, conditions, and disorders, such as cancer, that involve abnormal Raf activity. In some embodiments, compound A is a B-Raf inhibitor.
[0033] The preparation and use of compound A have been previously described (see WO2013 / 032951, US9,295,671, US9,572,808, US10,137,125, and US10,561,652, each of which is referenced in whole).
[0034] In some embodiments disclosed herein, compound A is crystalline.
[0035] Where used herein, “crystalline form,” “polymorph,” “form,” and “form” may be used interchangeably herein and mean all crystalline and amorphous forms of a compound, including, for example, polymorphs, pseudopolymorphs, salts, solvates, hydrates, non-solvated polymorphs (including anhydrous), conformational polymorphs, and amorphous forms, as well as mixtures thereof, unless a specific crystalline or amorphous form is mentioned. The compounds of this disclosure include, for example, polymorphs, pseudopolymorphs, solvates, hydrates, non-solvated polymorphs (including anhydrous), conformational polymorphs, and amorphous forms of the compound, as well as mixtures thereof, in crystalline and amorphous forms. In some embodiments, the crystalline form is a single solid form, e.g., crystalline form I.
[0036] I. Crystalline form of compound A Polymorphs produced by the method of the present invention can be characterized by any methodology in the art. For example, polymorphs produced by the method of the present invention can be characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), hot-stage microscopy, and / or spectroscopy (e.g., Raman spectroscopy, solid nuclear magnetic resonance spectroscopy (ssNMR), and infrared spectroscopy (IR)). In some embodiments, the crystallinity of the solid form is determined by X-ray powder diffraction (XRPD).
[0037] XRPD The polymorphs according to the present invention can be characterized by XRPD. The relative intensity of the XRPD peaks may vary depending on the particle size, sample preparation technique, sample mounting procedure, and the specific instrument used. Furthermore, instrument variations and other factors may affect the 2-θ value. Therefore, the XRPD peak assignment may vary, for example, by plus or minus approximately 0.2 degrees.
[0038] DSC The polymorphs according to the present invention may also be identified by their characteristic DSC thermograms, as shown in Figures 2 and 5. Regarding DSCs, it is known that the observed temperature depends on the rate of temperature change, as well as the sample preparation technique and the specific instruments used. The values reported herein with respect to DSC thermograms may vary, for example, by approximately plus or minus 4°C.
[0039] TGA The polymorphs of the present invention may also exhibit different thermal behavior from those of amorphous materials or other polymorphs. Thermal behavior can be measured in the laboratory by thermogravimetric analysis (TGA), which can be used to distinguish some polymorphs from others. In one embodiment, the polymorphs may be characterized by thermogravimetric analysis.
[0040] The polymorphs of compound A are useful in the manufacture of medicinal preparations and may be obtained by crystallization processes to produce crystalline and semicrystalline forms, or by solidification processes to obtain amorphous forms. In various embodiments, crystallization is carried out by generating the desired compound (e.g., compound A) in a reaction mixture and isolating the desired polymorph from the reaction mixture, or optionally by dissolving the raw compound in a solvent using heat, followed by cooling (including active cooling) and / or adding an anti-solvent for a period of time to crystallize / solidify the product. Following crystallization or solidification, drying may be carried out under controlled conditions until the desired water content is achieved in the final polymorph.
[0041] In various embodiments, the various polymorphs disclosed herein (e.g., crystalline forms I and II of compound A) are stable at room temperature. In some examples, the various polymorphs can be stored at room temperature for extended periods without significant chemical degradation or chemical changes to the crystalline form. In some examples, the various polymorphs can be stored at room temperature for periods of at least about 10, 30, 60, 90, 120, 150, or 180 days. In some examples, the various polymorphs can be stored at room temperature for periods exceeding about 180 days. In some examples, various polymorphs take 10-14 days, 10-18 days, 10-22 days, 10-26 days, 10-30 days, 10-40 days, 10-50 days, 10-60 days, 10-90 days, 10-120 days, 10-150 days, 10-180 days, 14-18 days, 14-22 days, 14-26 days, 14-30 days, 14-40 days, 14-50 days at room temperature. Day, 14-60 days, 14-90 days, 14-120 days, 14-150 days, 14-180 days, 18-22 days, 18-26 days, 18-30 days, 18-40 days, 18-50 days, 18-60 days, 18-90 days, 18-120 days, 18-150 days, 18-180 days, 22-26 days, 22-30 days, 22-40 days, 22-50 days, 22-60 days, 22-90 days, 22-120 days, 22-150 days, 22-180 days, 26-30 days, 26-40 days, 26-50 days, 26-60 days, 26-90 days, 26-120 days, 26-150 days, 26-180 days, 30-40 days, 30-50 days, 30-60 days, 30-90 days, 30-120 days, 30-150 days, 30-180 days, 40-50 days , 40-60 days, 40-90 days, 40-120 days, 40-150 days, 40-180 days, 50-60 days, 50-90 days, 50-120 days, 50-150 days, 50-180 days, 60-90 days, 60-120 days, 60-150 days, 60-180 days, 90-120 days, 90-150 days, or 90-180 days. In some examples, various polymorphs can be stored at room temperature for a period of at least 10 days, 14 days, 18 days, 22 days, 26 days, 30 days, 40 days, 50 days, 60 days, 90 days, 120 days, 150 days, or 180 days.
[0042] In various embodiments, the various polymorphs disclosed herein (e.g., crystalline forms I and II of compound A) are stable at temperatures above room temperature and / or high relative humidity (RH). In some examples, the various polymorphs disclosed herein (e.g., crystalline forms I and II of compound A) can be stored for extended periods at about 40°C and about 75% RH without significant chemical decomposition or alteration of the crystalline form. In some examples, the various polymorphs disclosed herein (e.g., crystalline forms I and II of compound A) can be stored at 40°C and about 75% RH for periods of at least about 10, 30, 60, 90, 120, 150, or 180 days. In some examples, the various polymorphs disclosed herein (e.g., crystalline forms I and II of compound A) can be stored at 40°C and about 75% RH for periods exceeding about 180 days.In some examples, the various polymorphic forms disclosed herein (e.g., crystalline forms I and II of compound A) are 10-14 days, 10-18 days, 10-22 days, 10-26 days, 10-30 days, 10-40 days, 10-50 days, 10-60 days, 10-90 days, 10-120 days, 10-150 days, 10-180 days, 14-18 days, 14-22 days, 14-26 days. 14-30, 14-40, 14-50, 14-60, 14-90, 14-120, 14-150, 14-180, 18-22, 18-26, 18-30, 18-40, 18-50, 18-60, 18-90, 18-120, 18-150, 18-180, 22-26, 22-30, 22-40, 22-5 0 days, 22-60 days, 22-90 days, 22-120 days, 22-150 days, 22-180 days, 26-30 days, 26-40 days, 26-50 days, 26-60 days, 26-90 days, 26-120 days, 26-150 days, 26-180 days, 30-40 days, 30-50 days, 30-60 days, 30-90 days, 30-120 days, 30-150 days, 30-180 days, 40-50 days, The compounds can be stored at 40°C and about 75% RH for periods of 40-60 days, 40-90 days, 40-120 days, 40-150 days, 40-180 days, 50-60 days, 50-90 days, 50-120 days, 50-150 days, 50-180 days, 60-90 days, 60-120 days, 60-150 days, 60-180 days, 90-120 days, 90-150 days, or 90-180 days. In some examples, the various polymorphic forms disclosed herein (e.g., crystalline form I and crystalline form II of compound A) can be stored at 40°C and about 75% RH for periods of at least 10, 14, 18, 22, 26, 30, 40, 50, 60, 90, 120, 150, or 180 days.
[0043] Crystal morphology of compound A I Figure 1 shows the X-ray powder diffraction (XRPD) pattern for crystalline form I of compound A.
[0044] Figure 2 shows the differential scanning calorimetry (DSC) thermogram for crystalline form I of compound A.
[0045] Figure 3 shows the thermogravimetric analysis (TGA) thermogram for crystalline form I of compound A.
[0046] In one embodiment, crystalline form I of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide is provided herein. Several embodiments provide compositions comprising crystalline form I of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide. In some embodiments, crystalline form I of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide is, (a) X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, including peaks at 8.7±0.2°²-θ, 21.6±0.2°²-θ, and 24.4±0.2°²-θ. (b) A substantially the same X-ray powder diffraction pattern as shown in Figure 1, (c) A differential scanning calorimetry (DSC) thermogram including endothermic temperatures in the range of approximately 180-190°C, (d) A differential scanning calorimetry (DSC) thermogram including endothermic heating with an onset of approximately 184°C and a peak of approximately 187°C, (e) A differential scanning calorimetry (DSC) thermogram that is substantially the same as the one shown in Figure 2, (f) A thermogravimetric analysis (TGA) thermogram that is substantially the same as the one shown in Figure 3, (g) XRPD that remains unchanged after being stored at 40°C and 75% relative humidity (RH) for 6 months, XRPDs that remain unchanged after being stored for 6 months at (h)25°C and relative humidity (RH)60%, or (i) Characterized as having a combination of those.
[0047] In some embodiments, crystalline morphology I is characterized by an X-ray powder diffraction pattern substantially identical to that shown in Figure 1.
[0048] In some embodiments, crystalline morphology I is characterized by an X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, containing peaks at 8.7±0.2°²-θ, 21.6±0.2°²-θ, and 24.4±0.2°²-θ. In some embodiments, crystalline morphology I is characterized by an X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, containing peaks at 8.7±0.1°²-θ, 21.6±0.1°²-θ, and 24.4±0.1°²-θ. In some embodiments, crystalline morphology I is characterized by an X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, containing peaks at approximately 8.7°²-θ, approximately 21.6°²-θ, and approximately 24.4°²-θ.
[0049] In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 17.5±0.2°²-θ, 14.6±0.2°²-θ, and 19.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 17.5±0.1°²-θ, 14.6±0.1°²-θ, and 19.3±0.1°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from about 17.5°²-θ, about 14.6°²-θ, and about 19.3°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å.
[0050] In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 23.1±0.1°²-θ, 16.0±0.1°²-θ, and 25.7±0.1°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from about 23.1°²-θ, about 16.0°²-θ, and about 25.7°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å.
[0051] In some embodiments, the X-ray powder diffraction pattern includes at least one peak selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least two peaks selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least three peaks selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least four peaks selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least five peaks selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å.In some embodiments, the X-ray powder diffraction pattern includes at least six peaks selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least seven peaks selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least eight peaks selected from 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, includes peaks at 8.7±0.2°²-θ, 21.6±0.2°²-θ, 24.4±0.2°²-θ, 17.5±0.2°²-θ, 14.6±0.2°²-θ, 19.3±0.2°²-θ, 23.1±0.2°²-θ, 16.0±0.2°²-θ, and 25.7±0.2°²-θ. In some embodiments, the X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, includes peaks at 8.7±0.1°2-θ, 21.6±0.1°2-θ, 24.4±0.1°2-θ, 17.5±0.1°2-θ, 14.6±0.1°2-θ, 19.3±0.1°2-θ, 23.1±0.1°2-θ, 16.0±0.1°2-θ, and 25.7±0.1°2-θ.In some embodiments, the X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, includes peaks at approximately 8.7°²-θ, approximately 21.6°²-θ, approximately 24.4°²-θ, approximately 17.5°²-θ, approximately 14.6°²-θ, approximately 19.3°²-θ, approximately 23.1°²-θ, approximately 16.0°²-θ, and approximately 25.7°²-θ.
[0052] In some embodiments, crystalline morphology I is characterized by a differential scanning calorimetry (DSC) thermogram substantially identical to that shown in Figure 2. In some embodiments, crystalline morphology I is characterized by a differential scanning calorimetry (DSC) thermogram that includes endothermic heat in the range of about 180–190°C. In some embodiments, crystalline morphology I is characterized by a differential scanning calorimetry (DSC) thermogram that includes endothermic heat with an onset of about 184°C and a peak of about 187°C.
[0053] In some embodiments, crystalline morphology I is approximately 160-180°C, 162-180°C, 164-180°C, 166-180°C, 168-180°C, 170-180°C, 172-180°C, 174-180°C, 160-178°C, 162-178°C, 164-178°C, 166-178°C, 168-178°C, 170-178°C, 172-178°C, 174-178°C, 160-176°C, 162-176°C, 164-176°C, 166-176°C, 168-176°C, 170-176°C, 172-176°C, 174-176°C, 160-174°C, 16 2-174℃, 164-174℃, 166-174℃, 168-174℃, 170-174℃, 172-174℃, 160-172℃, 162-172℃, 164-172℃, 166-172℃, 168-172℃, 170-172℃, 160-170℃, 162-170℃, 164-170 Crystal morphology I is characterized by endothermic activity at 166-170°C, 168-170°C, 160-168°C, 162-168°C, 164-168°C, 166-168°C, 160-166°C, 162-166°C, 162-166°C, 164-166°C, 160-164°C, 162-164°C, and 160-162°C. In various embodiments, crystal morphology I is characterized by endothermic activity at approximately 180-190°C in a DSC thermogram, for example, approximately 180°C, 181°C, 181°C, 183°C, 184°C, 185°C, 186°C, 187°C, 188°C, 189°C, or 190°C. In some embodiments, the melting point of crystal morphology I is approximately 187°C.
[0054] In some embodiments, crystalline morphology I is characterized by a thermogravimetric analysis (TGA) thermogram substantially identical to that shown in Figure 3. In various embodiments, crystalline morphology I decomposes at temperatures above approximately 200°C, 250°C, 300°C, 350°C, 400°C, 450°C, 500°C, 550°C, or 600°C. In some examples, crystalline morphology I decomposes at temperatures above approximately 250°C.
[0055] In some embodiments, crystalline form I is characterized by an XRPD that remains unchanged after storage at 40°C and 75% relative humidity (RH) for 6 months. In some embodiments, crystalline form I is characterized by an XRPD that is substantially the same as that shown in Figure 6 after storage at 40°C and 75% relative humidity (RH) for 6 months. In some embodiments, crystalline form I is characterized by a DSC that remains unchanged after storage at 40°C and 75% relative humidity (RH) for 6 months. In some embodiments, crystalline form I is characterized by a DSC that is substantially the same as that shown in Figure 7 after storage at 40°C and 75% relative humidity (RH) for 6 months.
[0056] In some embodiments, crystalline form I is characterized by an XRPD that remains unchanged after storage at 25°C and 60% relative humidity (RH) for 6 months. In some embodiments, crystalline form I is characterized by an XRPD that is substantially the same as that shown in Figure 8 after storage at 25°C and 60% relative humidity (RH) for 6 months. In some embodiments, crystalline form I is characterized by a DSC that remains unchanged after storage at 25°C and 60% relative humidity (RH) for 6 months. In some embodiments, crystalline form I is characterized by a DSC that is substantially the same as that shown in Figure 9 after storage at 25°C and 60% relative humidity (RH) for 6 months.
[0057] In various embodiments, crystalline form I is stable at room temperature. In some examples, crystalline form I can be stored at room temperature for extended periods without significant chemical decomposition or change of the crystalline form. In some examples, crystalline form I can be stored at room temperature for periods of at least about 10, 30, 60, 90, 120, 150, or 180 days. In some examples, crystalline form I can be stored at room temperature for periods exceeding about 180 days. In some examples, crystalline form I can be stored at room temperature for 10-14 days, 10-18 days, 10-22 days, 10-26 days, 10-30 days, 10-40 days, 10-50 days, 10-60 days, 10-90 days, 10-120 days, 10-150 days, 10-180 days, 14-18 days, 14-22 days, 14-26 days, 14-30 days, 14-40 days, 14-50 days. , 14-60 days, 14-90 days, 14-120 days, 14-150 days, 14-180 days, 18-22 days, 18-26 days, 18-30 days, 18-40 days, 18-50 days, 18-60 days, 18-90 days, 18-120 days, 18-150 days, 18-180 days, 22-26 days, 22-30 days, 22-40 days, 22-50 days, 22-60 days, 2 2-90 days, 22-120 days, 22-150 days, 22-180 days, 26-30 days, 26-40 days, 26-50 days, 26-60 days, 26-90 days, 26-120 days, 26-150 days, 26-180 days, 30-40 days, 30-50 days, 30-60 days, 30-90 days, 30-120 days, 30-150 days, 30-180 days, 40-50 days, Crystal morphology I can be stored for periods of 40-60 days, 40-90 days, 40-120 days, 40-150 days, 40-180 days, 50-60 days, 50-90 days, 50-120 days, 50-150 days, 50-180 days, 60-90 days, 60-120 days, 60-150 days, 60-180 days, 90-120 days, 90-150 days, or 90-180 days. In some cases, crystalline morphology I can be stored at room temperature for periods of at least 10 days, 14 days, 18 days, 22 days, 26 days, 30 days, 40 days, 50 days, 60 days, 90 days, 120 days, 150 days, or 180 days.
[0058] In various embodiments, crystalline form I is stable at temperatures higher than room temperature and / or at high RH. In some examples, crystalline form I can be stored for extended periods at about 40°C and about 75% RH without significant chemical decomposition or change of the crystalline form. In some examples, crystalline form I can be stored at 40°C and about 75% RH for periods of at least about 10, 30, 60, 90, 120, 150, or 180 days. In some examples, crystalline form I can be stored at 40°C and about 75% RH for periods exceeding about 180 days. In some cases, crystalline form I develops at 40°C and approximately 75% RH in 10-14 days, 10-18 days, 10-22 days, 10-26 days, 10-30 days, 10-40 days, 10-50 days, 10-60 days, 10-90 days, 10-120 days, 10-150 days, 10-180 days, 14-18 days, 14-22 days, 14-26 days, 14-30 days, and 14-40 days. , 14-50 days, 14-60 days, 14-90 days, 14-120 days, 14-150 days, 14-180 days, 18-22 days, 18-26 days, 18-30 days, 18-40 days, 18-50 days, 18-60 days, 18-90 days, 18-120 days, 18-150 days, 18-180 days, 22-26 days, 22-30 days, 22-40 days, 22-50 days, 22- 60 days, 22-90 days, 22-120 days, 22-150 days, 22-180 days, 26-30 days, 26-40 days, 26-50 days, 26-60 days, 26-90 days, 26-120 days, 26-150 days, 26-180 days, 30-40 days, 30-50 days, 30-60 days, 30-90 days, 30-120 days, 30-150 days, 30-180 days, 40-5 Crystal morphology I can be stored for periods of 0 days, 40-60 days, 40-90 days, 40-120 days, 40-150 days, 40-180 days, 50-60 days, 50-90 days, 50-120 days, 50-150 days, 50-180 days, 60-90 days, 60-120 days, 60-150 days, 60-180 days, 90-120 days, 90-150 days, or 90-180 days. In some cases, crystalline morphology I can be stored at 40°C and approximately 75% RH for periods of at least 10 days, 14 days, 18 days, 22 days, 26 days, 30 days, 40 days, 50 days, 60 days, 90 days, 120 days, 150 days, or 180 days.
[0059] In various embodiments, crystalline form I is stable at temperatures above room temperature and / or at high RH. In some examples, crystalline form I can be stored for extended periods at about 25°C and about 60% RH without significant chemical decomposition or change of the crystalline form. In some examples, crystalline form I can be stored at 25°C and about 60% RH for periods of at least about 10, 30, 60, 90, 120, 150, or 180 days. In some examples, crystalline form I can be stored at 25°C and about 60% RH for periods exceeding about 180 days. In some cases, crystalline form I develops at 25°C and approximately 60% RH in 10-14 days, 10-18 days, 10-22 days, 10-26 days, 10-30 days, 10-40 days, 10-50 days, 10-60 days, 10-90 days, 10-120 days, 10-150 days, 10-180 days, 14-18 days, 14-22 days, 14-26 days, 14-30 days, and 14-40 days. , 14-50 days, 14-60 days, 14-90 days, 14-120 days, 14-150 days, 14-180 days, 18-22 days, 18-26 days, 18-30 days, 18-40 days, 18-50 days, 18-60 days, 18-90 days, 18-120 days, 18-150 days, 18-180 days, 22-26 days, 22-30 days, 22-40 days, 22-50 days, 22- 60 days, 22-90 days, 22-120 days, 22-150 days, 22-180 days, 26-30 days, 26-40 days, 26-50 days, 26-60 days, 26-90 days, 26-120 days, 26-150 days, 26-180 days, 30-40 days, 30-50 days, 30-60 days, 30-90 days, 30-120 days, 30-150 days, 30-180 days, 40-5 Crystal morphology I can be stored for periods of 0 days, 40-60 days, 40-90 days, 40-120 days, 40-150 days, 40-180 days, 50-60 days, 50-90 days, 50-120 days, 50-150 days, 50-180 days, 60-90 days, 60-120 days, 60-150 days, 60-180 days, 90-120 days, 90-150 days, or 90-180 days. In some cases, crystalline morphology I can be stored at 25°C, approximately 92.5% RH, for periods of at least 10 days, 14 days, 18 days, 22 days, 26 days, 30 days, 40 days, 50 days, 60 days, 90 days, 120 days, 150 days, or 180 days.
[0060] Crystal form II of compound A Figure 4 shows the X-ray powder diffraction (XRPD) pattern of compound A for crystalline form II.
[0061] Figure 5 shows the differential scanning calorimetry (DSC) thermogram of compound A against crystalline form II.
[0062] In one embodiment, crystalline form II of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide is provided herein. Several embodiments provide compositions comprising crystalline form II of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide. In some embodiments, crystalline form II of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide is, (a) X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, including peaks at 11.8 ± 0.2°²-θ, 8.6 ± 0.2°²-θ, and 15.1 ± 0.2°²-θ. (b) A substantially the same X-ray powder diffraction pattern as shown in Figure 4, (c) i) Endothermic temperature in the range of approximately 135-145°C, ii) Heat generation in the range of approximately 143-153°C, iii) Endothermic temperature range of 155~165°C and Differential scanning calorimetry (DSC) thermograms, (d) i) Endothermic with an onset of approximately 138°C and a peak of approximately 143°C, ii) Exothermic reaction with an onset of approximately 146°C and a peak of approximately 148°C, iii) Endothermic with an onset of approximately 158°C and a peak of approximately 160°C Differential scanning calorimetry (DSC) thermograms, (e) A differential scanning calorimetry (DSC) thermogram substantially identical to that shown in Figure 5, or (j) Characterized by having a combination of those.
[0063] In some embodiments, crystalline form II is characterized by an X-ray powder diffraction pattern substantially identical to that shown in Figure 4.
[0064] In some embodiments, crystalline form II is characterized by an X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, containing peaks at 11.8±0.2°²-θ, 8.6±0.2°²-θ, and 15.1±0.2°²-θ. In some embodiments, crystalline form II is characterized by an X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, containing peaks at 11.8±0.1°²-θ, 8.6±0.1°²-θ, and 15.1±0.1°²-θ. In some embodiments, crystalline form II is characterized by an X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, containing peaks at approximately 11.8°²-θ, approximately 8.6°²-θ, and approximately 15.1°²-θ.
[0065] In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 17.2±0.2°²-θ, 9.3±0.2°²-θ, and 23.6±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 17.2±0.1°²-θ, 9.3±0.1°²-θ, and 23.6±0.1°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from about 17.2°²-θ, about 9.3°²-θ, and about 23.6°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å.
[0066] In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from 21.5±0.1°²-θ, 22.2±0.1°²-θ, and 14.3±0.1°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern further includes at least one peak selected from about 21.5°²-θ, about 22.2°²-θ, and about 14.3°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å.
[0067] In some embodiments, the X-ray powder diffraction pattern includes peaks selected from 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least two peaks selected from 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least three peaks selected from 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least four peaks selected from 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least five peaks selected from 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å.In some embodiments, the X-ray powder diffraction pattern includes at least six peaks selected from 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least seven peaks selected from 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern includes at least eight peaks selected from 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å. In some embodiments, the X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, includes peaks at 11.8±0.2°²-θ, 8.6±0.2°²-θ, 15.1±0.2°²-θ, 17.2±0.2°²-θ, 9.3±0.2°²-θ, 23.6±0.2°²-θ, 21.5±0.2°²-θ, 22.2±0.2°²-θ, and 14.3±0.2°²-θ. In some embodiments, the X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, includes peaks at 11.8±0.1°2-θ, 8.6±0.1°2-θ, 15.1±0.1°2-θ, 17.2±0.1°2-θ, 9.3±0.1°2-θ, 23.6±0.1°2-θ, 21.5±0.1°2-θ, 22.2±0.1°2-θ, and 14.3±0.1°2-θ.In some embodiments, the X-ray powder diffraction pattern, measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å, includes peaks at approximately 11.8°²-θ, approximately 8.6°²-θ, approximately 15.1°²-θ, approximately 17.2°²-θ, approximately 9.3°²-θ, approximately 23.6°²-θ, approximately 21.5°²-θ, approximately 22.2°²-θ, and approximately 14.3°²-θ.
[0068] In some embodiments, crystalline morphology II features a differential scanning calorimetry (DSC) thermogram substantially identical to that shown in Figure 5. In some embodiments, crystalline morphology II features a differential scanning calorimetry (DSC) thermogram including endothermic activity in the range of approximately 135–145°C, exothermic activity in the range of approximately 143–153°C, and endothermic activity in the range of 155–165°C. In some embodiments, crystalline morphology II features a differential scanning calorimetry (DSC) thermogram including endothermic activity with an onset of approximately 138°C and a peak at approximately 143°C, exothermic activity with an onset of approximately 146°C and a peak at approximately 148°C, and endothermic activity with an onset of approximately 158°C and a peak at approximately 160°C.
[0069] In some embodiments, crystalline form II is characterized by endothermic activity in a DSC thermogram in the range of approximately 130-160°C, for example, approximately 130-160°C, 130-155°C, 130-150°C, 130-145°C, 130-140°C, 130-135°C, 135-160°C, 135-155°C, 135-145°C, 135-140°C, 140-160°C, 140-155°C, 140-145°C, 145-160°C, 145-155°C, 145-155°C, 150-160°C, 150-155°C, or 155-160°C. In some cases, crystal morphology II is characterized by endothermic activity at approximately 143°C in DSC thermograms.
[0070] In some embodiments, crystalline form II is characterized by exothermic reaction in a DSC thermogram in the range of approximately 135-165°C, for example, approximately 135-165°C, 135-160°C, 135-155°C, 135-155°C, 135-145°C, 135-140°C, 140-165°C, 140-160°C, 140-155°C, 140-145°C, 145-165°C, 145-165°C, 145-155°C, 145-155°C, 150-165°C, 155-155°C, 155-165°C, or 160-165°C. In some cases, crystal morphology II is characterized by exothermic activity at approximately 148°C in DSC thermograms.
[0071] In some embodiments, crystalline form II is further characterized in the DSC thermogram by endothermic activity in the range of approximately 150-180°C, for example, approximately 150-175°C, 150-170°C, 150-165°C, 150-160°C, 155-155°C, 155-180°C, 155-175°C, 155-170°C, 155-165°C, 155-160°C, 160-180°C, 160-175°C, 160-170°C, 160-165°C, 165-180°C, 165-175°C, 165-170°C, 170-180°C, 170-175°C, or 175-180°C. In some examples, crystalline form II is further characterized in the DSC thermogram by endothermic activity at approximately 160°C.
[0072] II. Method for preparing compound A and its polymorphs In one embodiment, the present invention provides a method for producing one or more polymorphs of compound A.
[0073] [ka]
[0074] Compound A can be prepared as previously described in WO2013 / 032951, US9,295,671, US9,572,808, US10,137,125, and US10,561,652. In some embodiments, Compound A is prepared according to the examples herein.
[0075] The polymorphs according to the present invention are not limited by the starting materials used to produce compound A.
[0076] In one embodiment, the present invention relates to a method for producing polymorphs of compound A or pharmaceutically acceptable salts and / or solvates thereof by either isolating a desired polymorph as a first solid form after the synthesis of compound A, or by isolating a desired polymorph as a transition from a previous solid form of compound A. A transition from one form to another is within the scope of the present invention because it may be an alternative method of production to obtain a form desirable for the manufacture of a pharmaceutical formulation.
[0077] The polymorphs of compound A obtained by the method of the present invention may be selected from crystalline form I, crystalline form II, and mixtures thereof.
[0078] The isolation and purification of the chemical entities and intermediates described herein may be carried out by any suitable separation or purification procedure, if desired, such as filtration, extraction, crystallization, column chromatography, thin-layer chromatography, or thick-layer chromatography, or a combination thereof. Specific examples of suitable separation and isolation procedures may be given by referring to the following examples. However, other equivalent separation or isolation procedures may also be used. Prior to crystallization, compound A can be isolated with a chemical purity of approximately 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, approximately 98%, or approximately 100%.
[0079] In some embodiments, the crystalline forms disclosed herein are obtained by crystallizing compound A to a chemical purity of less than about 98%, less than about 97%, less than about 96%, less than about 95%, less than about 94%, less than about 93%, less than about 92%, less than about 91%, less than about 90%, less than about 89%, less than about 88%, less than about 87%, less than about 86%, less than about 85%, less than about 84%, less than about 83%, less than about 82%, less than about 81%, less than about 80%, less than about 78%, less than about 76%, less than about 74%, less than about 72%, or less than about 70%. In some embodiments, the crystalline form is obtained by crystallizing compound A to a chemical purity in the range of about 70% to about 99%, 80% to about 96%, about 85% to about 96%, about 90% to about 96%, about 80% to about 98%, about 85% to about 98%, about 90% to about 98%, about 92% to about 98%, about 94% to 98%, or about 96% to about 98%.
[0080] Preparation of Crystal Form I In one embodiment, the desired polymorph is crystalline form I of compound A, and the isolation step involves recrystallization of the crude reaction product from a monosolvent system. In various embodiments, the desired polymorph is crystalline form I of compound A, and the isolation step involves recrystallization of the crude product from a binary, ternary, or more solvent system, which is understood collectively as a polysolvent system. In various embodiments, the desired polymorph is crystalline form I of compound A, and the isolation step involves crystallization from a monosolvent or polysolvent system, which involves dissolving compound A in a monosolvent or polysolvent system at a temperature higher than ambient temperature. In some cases, the solubility of compound A in monosolvent or multisolvent systems is approximately 40-90°C, 45-90°C, 50-90°C, 55-90°C, 60-90°C, 65-90°C, 70-90°C, 75-90°C, 40-85°C, 45-85°C, 50-85°C, 55-85°C, 65-85°C, 70-85°C, 75-85°C, 80-85°C, 40-80°C, 45-80°C, 50-80°C, 55-80°C, 60-80°C, 65-80°C, 70-80°C, 75- The process is carried out at temperatures of 80°C, 40-75°C, 45-75°C, 50-75°C, 55-75°C, 60-75°C, 65-75°C, 70-75°C, 40-70°C, 45-70°C, 50-70°C, 55-70°C, 60-70°C, 65-70°C, 40-65°C, 45-65°C, 50-65°C, 55-65°C, 60-65°C, 40-60°C, 45-60°C, 50-60°C, 55-60°C, 40-55°C, 45-55°C, 50-55°C, 40-50°C, or 45-50°C. In some examples, the recrystallization solvent contains ethyl acetate, and the dissolution of compound A into the solvent is carried out at temperatures of approximately 75-85°C. Any suitable amount of solvent can be used to dissolve compound A. In some embodiments, the amount of solvent (e.g., ethyl acetate) used to dissolve the compound is about 1 to 10 mL per gram of compound A. For example, in some embodiments, the amount of solvent used to dissolve compound A is 4 mL per gram of compound A. In some examples, the recrystallization solvent contains ethyl acetate, the dissolution of compound A into the solvent system is carried out at a temperature of about 75 to 85°C, and the amount of solvent used for dissolution is about 4 mL / g of compound A.
[0081] In various embodiments, crystallization further involves actively heating the solution containing the dissolved compound A to a temperature of, for example, about 40-100°C, 40-90°C, 40-80°C, 40-70°C, 40-60°C, 40-50°C, 50-100°C, 50-90°C, 50-80°C, 50-70°C, 50-60°C, 60-100°C, 60-90°C, 60-80°C, 60-70°C, 70-100°C, 70-90°C, 70-80°C, 80-100°C, or 80-90°C. In some embodiments, the solution containing the dissolved compound A is heated to a temperature of about 75-85°C. In various embodiments, the solution containing dissolved compound A is maintained at a heating temperature for a certain period of time, for example, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours or more.
[0082] In various embodiments, crystallization further involves actively cooling the heated solution containing dissolved compound A to a temperature of, for example, about 0-40°C, 0-30°C, 0-20°C, 0-10°C, 10-40°C, 10-30°C, 10-20°C, 20-40°C, 20-30°C, 20-10°C, or 30-40°C. In some embodiments, crystallization further involves actively cooling the heated solution containing dissolved compound A to a temperature of about 20-30°C. In various embodiments, the solution containing the dissolved compound A is further maintained at this lower temperature for a period of time, for example, about 30 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours or more.
[0083] In various embodiments, the active heating and subsequent active cooling steps are repeated multiple times, for example, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten times. In some embodiments, the active heating and subsequent active cooling steps are repeated two, three, four, five, six, seven, eight, nine, or ten times.
[0084] In various embodiments, crystallization further involves filtering the solution containing the resulting crystals of compound A. In some embodiments, crystallization optionally involves washing the resulting crystals with a solvent, for example, a recrystallization solvent, one or more times. In some embodiments, crystallization optionally involves drying the resulting crystals, for example, under vacuum at a temperature of about 40-50°C.
[0085] In some embodiments, the chemical purity of crystalline form I exceeds 60%, 70%, 80%, 90%, 95%, or 99%. In some embodiments, the chemical purity of crystalline form I exceeds about 90%. In some embodiments, the chemical purity of crystalline form I exceeds about 95%. In some embodiments, the chemical purity of crystalline form I exceeds about 99%. The chemical purity of crystalline form I can be measured by any available analytical technique, for example, by HPLC analysis.
[0086] In various embodiments, crystalline form I is dry. In various embodiments, crystalline form I is not solvated. In various embodiments, crystalline form I is not hydrated. In various embodiments, crystalline form I is anhydrous.
[0087] Preparation of Crystal Form II In one embodiment, the desired polymorph is crystalline form II of compound A, and the isolation step involves recrystallization of the crude reaction product from a monosolvent system. In various embodiments, the desired polymorph is crystalline form II of compound A, and the isolation step involves recrystallization of the crude product from a binary, ternary, or more solvent system, which can be understood collectively as a multisolvent system. In various embodiments, the desired polymorph is crystalline form II of compound A, and the isolation step involves crystallization from a monosolvent system or a multisolvent system. In some cases, the dissolution of compound A in monosolvent or multisolvent systems is approximately 10-50°C, 10-45°C, 10-40°C, 10-35°C, 10-30°C, 10-25°C, 10-20°C, 10-15°C, 15-50°C, 15-45°C, 15-40°C, 15-35°C, 15-30°C, 15-25°C, 15-20°C, 20-50°C, 20- The process is carried out at temperatures of 45°C, 20-40°C, 20-35°C, 20-30°C, 20-25°C, 25-50°C, 25-45°C, 25-40°C, 25-35°C, 25-30°C, 30-50°C, 30-45°C, 30-40°C, 30-35°C, 35-50°C, 35-45°C, 35-40°C, 40-50°C, 40-45°C, or 45-50°C. In some examples, the recrystallization solvent contains ethyl acetate, and the dissolution of compound A into the solvent is carried out at temperatures of approximately 10-20°C. Any suitable amount of solvent may be used to dissolve compound A. In some embodiments, the amount of solvent (e.g., ethyl acetate) used to dissolve the compound is approximately 1-10 mL per gram of compound A. For example, in some embodiments, the amount of solvent used to dissolve compound A is 1.5 mL per gram of compound A. In some examples, the recrystallization solvent contains ethyl acetate, the dissolution of compound A into the solvent system is carried out at a temperature of approximately 10–20°C, and the amount of solvent used for dissolution is approximately 1.5 mL / g of compound A.
[0088] In various embodiments, crystallization further involves filtering the solution containing the resulting crystals of compound A. In some embodiments, crystallization optionally involves washing the resulting crystals with a solvent, for example, a recrystallization solvent, one or more times. In some embodiments, crystallization optionally involves drying the resulting crystals, for example, under vacuum at a temperature of about 50-60°C.
[0089] In some embodiments, the chemical purity of crystalline form II exceeds 60%, 70%, 80%, 90%, 95%, or 99%. In some embodiments, the chemical purity of crystalline form II exceeds about 90%. In some embodiments, the chemical purity of crystalline form II exceeds about 95%. In some embodiments, the chemical purity of crystalline form II exceeds about 99%. The chemical purity of crystalline form II can be measured by any available analytical technique, for example, by HPLC analysis.
[0090] III. Additional Definitions As used herein, “activator” is used to indicate a chemical substance having biological activity. In certain embodiments, “activator” is a compound having pharmaceutical utility. For example, an activator may be an anticancer drug.
[0091] As used herein, “modulation” refers to a change in activity as a direct or indirect response to the presence of a chemical substance described herein, compared to the activity in the absence of the chemical substance. The change may be an increase or decrease in activity and may result from a direct interaction between the compound and the target, or from an interaction between the compound and one or more other factors that affect the activity of the target. For example, the presence of a chemical substance may increase or decrease target activity, for example, by directly binding to the target, by causing (directly or indirectly) another factor that increases or decreases target activity, or by (directly or indirectly) increasing or decreasing the amount of the target present in a cell or organism.
[0092] As used herein, the “therapeutic dose” of a chemical substance described herein means an amount that, when administered to a human or non-human subject, is effective in providing a therapeutic benefit, such as improvement of symptoms, delay of disease progression, or prevention of disease.
[0093] "To treat" or "treatment" encompasses the administration of compound A or a pharmaceutically acceptable salt thereof to a mammalian subject, particularly a human subject, that requires such administration, and includes (i) inhibiting the progression of clinical symptoms of a disease such as cancer, (ii) causing regression of clinical symptoms of a disease such as cancer, and / or (iii) prophylactic treatment to prevent the onset of a disease such as cancer.
[0094] As used herein, a “pharmaceutically acceptable” ingredient is suitable for use in humans and / or animals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions) that are commensurate with a reasonable benefit-risk ratio.
[0095] "Pharmacologically acceptable salts" include, but are not limited to, salts with inorganic acids, such as hydrochlorides, carbonates, phosphates, hydrogen phosphates, diphosphates, hydrobromides, sulfates, sulfonates, nitrates, and similar salts, as well as salts with organic acids, such as malates, malonates, maleates, fumarates, tartrates, succinates, citrates, acetates, lactates, glucons, methanesulfonates, tris(hydroxymethylaminomethane), p-toluenesulfonates, propionates, 2-hydroxyethylsulfonates, benzoates, salicylates, stearates, oxalates, pamoates, alkanoates such as acetate HOOC-(CH2)n-COOH (where n is 0-4), and similar salts. Other salts include sulfates, metasulfons, bromides, trifluoroacetates, picrates, sorbates, benzylates, salicylates, nitrates, phthalates, or morpholine. Pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.
[0096] In addition, when the compounds described herein are obtained as acid addition salts, the free base can be obtained by basicizing a solution of the acid salt. Conversely, when the product is a free base, the addition salt, specifically a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, following conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize the various synthetic methods that can be used to prepare non-toxic, pharmaceutically acceptable addition salts.
[0097] As used herein, “subject” refers to a mammal that has been or will be the subject of treatment, observation, or experimentation. The methods described herein may be useful in both human therapeutic and veterinary applications. In some embodiments, the subject is human.
[0098] The term "mammal" is intended to have its standard meaning and includes, for example, humans, dogs, cats, sheep, and cows.
[0099] As described herein, “prodrug” includes any compound that, when administered to a subject, becomes compound A, for example, during the metabolic process of the prodrug. Similarly, “pharmaceutically acceptable salt” includes a “prodrug” of a pharmaceutically acceptable salt. Examples of prodrugs include derivatives of functional groups, such as carboxylic acid groups, in compound A. Exemplary prodrugs of carboxylic acid groups include, but are not limited to, carboxylic acid esters such as alkyl esters, hydroxyalkyl esters, arylalkyl esters, and aryloxyalkyl esters. Other exemplary prodrugs include lower alkyl esters such as ethyl esters, acyloxyalkyl esters such as pivaloyloxymethyl (POM), glycosides, and ascorbic acid derivatives. Other exemplary prodrugs include carboxylic acid amides. Discussions of prodrugs are provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACS Symposium Series, in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
[0100] The compounds disclosed herein are in different enriched isotopic forms, for example, 2 H, 3 H, 11 C, 13 C and / or 14The compound can be used in a concentrated form containing C. In one particular embodiment, the compound is deuterated at at least one position. Such a deuterated form can be produced by the procedures described in U.S. Patents No. 5,846,514 and 6,334,997. As described in U.S. Patents No. 5,846,514 and 6,334,997, deuteration can improve the efficacy of the drug and increase the duration of action.
[0101] Deuterium-substituted compounds can be synthesized using various methods, as described in Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [In:]:, Pharm., 2000; (10) 2000, 110pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.
[0102] A “solvate” is formed by the interaction of a solvent and a compound. The term “compound” is intended to include the solvates of compounds. Similarly, “pharmaceutically acceptable salt” includes the solvates of pharmaceutically acceptable salts. Suitable solvates are pharmaceutically acceptable solvates such as monohydrates and hemihydrates, as well as solvates formed using one or more crystallization solvents.
[0103] The pharmaceutically acceptable forms of the compounds described herein include pharmaceutically acceptable salts, chelates, non-covalent complexes, prodrugs, and mixtures thereof.
[0104] A "chelate" is formed by the coordination of a metal ion to two (or more) points in a compound. The term "compound" is intended to include chelates of compounds. Similarly, "pharmaceutically acceptable salt" includes chelates of pharmaceutically acceptable salts.
[0105] A "non-covalent complex" is formed by the interaction of a compound with another molecule, where no covalent bond is formed between the compound and the molecule. For example, complex formation may occur via van der Waals interactions, hydrogen bonds, and electrostatic interactions (also called ionic bonds). Such non-covalent complexes are included in the term "compound." Similarly, pharmaceutically acceptable salts include "non-covalent complexes" of pharmaceutically acceptable salts.
[0106] When the term "range" is used herein to refer to physical properties such as molecular weight, or chemical properties such as chemical formula, it is intended to include all combinations and partial combinations of the range, as well as specific embodiments herein.
[0107] The term "approximately" when referring to a number or range means that the number or range mentioned is an approximation within experimental variability (or statistical experimental error), and thus the number or range may vary, for example, between 1% and 15% of the stated number or range. In some examples of numerical ranges, "approximately" means ±10%.
[0108] As used herein, “significant” means any detectable change that is statistically significant in a standard parametric test of statistical significance, such as Student’s t-test, where p < 0.05.
[0109] As used herein, “cancer” means all types of cancer, neoplasms, or malignant tumors found in mammals, including carcinomas and sarcomas. Examples of cancers include brain, breast, cervical, colorectal, head and neck, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovarian, sarcoma, stomach, uterine, and medulloblastoma cancers.
[0110] As used herein, the terms “BRAF,” “B-Raf,” and “B-Raf” are used interchangeably to refer to a gene or the protein product of a gene.
[0111] IV. Treatment Methods In some embodiments, various polymorphs of compound A are Abl, Akt1, Akt2, Akt3, ALK, ALK5, A-Raf, B-Raf, Brk, Btk, Cdk2, CDK4, CDK5, CDK6, CHK1, c-Raf-1, Csk, EGFR, EphA1, EphA2, EphB2, EphB4, Erk2, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Flt1, Flt3, Flt4, Fms, Frk, Fyn, Gsk3α, Gsk3β, HCK, Her2 / Erbb2, Her4 / Erbb4, IGF1R, IKKβ, Irak4, I It binds to kinases including, but not limited to, tk, Jak1, Jak2, Jak3, Jnk1, Jnk2, Jnk3, Kdr, Kit, Lck, Lyn, MAP2K1, MAP2K2, MAP4K4, MAPKAPK2, Met, Mnk1, MLK1, p38, PDGFRA, PDGFRB, PDPK1Pim1, Pim2, Pim3, PKCα, PKCβ, PKCθ, Plk1, Pyk2, ROCK1, ROCK2, Ron, Src, Stk6, Syk, TEC, Tie2, TrkA, TrkB, Yes, and Zap70, as well as any variants thereof. For example, polymorphs of compound A bind to kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E variant, B-Raf V600E / T5291 variant, c-Raf-1, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Jnk1, Jnk2, Jnk3, Lck, Lyn, Met, Pim1, Pim2, Pim3, Pyk2, Kdr, Src, and Ret, as well as any variants thereof. In some embodiments, compound A binds to kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E variant, B-Raf V600E / T5291 variant, or c-Raf-1. For example, polymorphs of compound A bind to kinases that are B-Raf or B-Raf V600E variant.In some embodiments, polymorphs of compound A are measured in an in vitro assay at Kd levels lower than 50 μM, 25 μM, 10 μM, 5 μM, or 1 μM, and include Abl, Akt1, Akt2, Akt3, ALK, ALK5, A-Raf, B-Raf, Brk, Btk, Cdk2, CDK4, CDK5, CDK6, CHK1, c-Raf-1, Csk, EGFR, EphA1, EphA2, EphB2, EphB4, Erk2, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Flt1, Flt3, Flt4, Fms, Frk, Fyn, Gsk3α, Gsk3β, HCK, Her2 / Erbb2, Her4 / Erb It binds to kinases including, but not limited to, any variant thereof, having b4, IGF1R, IKKβ, Irak4, Itk, Jak1, Jak2, Jak3, Jnk1, Jnk2, Jnk3, Kdr, Kit, Lck, Lyn, MAP2K1, MAP2K2, MAP4K4, MAPKAPK2, Met, Mnk1, MLK1, p38, PDGFRA, PDGFRB, PDPK1, Pim1Pim2, Pim3, PKCα, PKCβ, PKCθ, Plk1, Pyk2, ROCK1, ROCK2, Ron, Src, Stk6, Syk, TEC, Tie2, TrkA, TrkB, Yes, and Zap70, (and) For example, polymorphs of compound A bind to kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E variant, B-Raf V600E / T5291 variant, c-Raf-1, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Jnk1, Jnk2, Jnk3, Lck, Lyn, Met, Pim1, Pim2, Pim3, Pyk2, Kdr, Src, and Ret, as well as any variants thereof, at Kd levels lower than 50 μM, 25 μM, 10 μM, 5 μM, or 1 μM, as measured in an in vitro assay. In some embodiments, polymorphs of compound A bind to kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E variant, B-Raf V600E / T5291 variant, or c-Raf-1 at Kd levels lower than 50 μM, 25 μM, 10 μM, 5 μM, or 1 μM, as measured in an in vitro assay.For example, polymorphs of compound A bind to kinases that are B-Raf or B-Raf V600E variants at Kd levels lower than 50 μM, 25 μM, 10 μM, 5 μM, or 1 μM, as measured in in vitro assays.
[0112] In some embodiments, polymorphs of compound A are Abl, Akt1, Akt2, Akt3, ALK, ALK5, A-Raf, B-Raf, Brk, Btk, Cdk2, CDK4, CDK5, CDK6, CHK1, c-Raf-1, Csk, EGFR, EphA1, EphA2, EphB2, EphB4, Erk2, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Flt1, Flt3, Flt4, Fms, Frk, Fyn, Gsk3α, Gsk3β, HCK, Her2 / Erbb2, Her4 / Erbb4, IGF1R, IKKβ, Irak4, I tk, Jak1, Jak2, Jak3, Jnk1, Jnk2, Jnk3, Kdr, Kit, Lck, Lyn, MAP2K1, MAP2K2, MAP4K4, MAPKAPK2, Met, Mnk1, MLK1, p38, PDGFRA, PDGFRB, PDPK1, Pim1, Pim2, Pim3, PKCα, PKCβ, PKCθ, Plk1, Pyk2, ROCK1, ROCK2, Ron, Src, Stk6, Syk, TEC, Tie2, TrkA, TrkB, Yes, and Zap70 inhibit kinases including, but not limited to, any of their mutant forms. For example, polymorphs of compound A inhibit kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E mutant, B-Raf V600E / T5291 mutant, c-Raf-1, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Jnk1, Jnk2, Jnk3, Lck, Lyn, Met, Pim1, Pim2, Pim3, Pyk2, Kdr, Src, and Ret, as well as any mutants thereof. In some embodiments, polymorphs of compound A inhibit kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E mutant, B-Raf V600E / T5291 mutant, or c-Raf-1. For example, polymorphs of compound A inhibit kinases that are B-Raf or B-Raf V600E mutant. In some embodiments, polymorphs of compound A are confirmed in in vitro kinase assays to have IC50 concentrations of 10 μM, 5 μM, 2 μM, 1 μM, 500 nM, 200 nM, 100 nM, 50 nM, 25 nM, 10 nM, 5 nM, or less in the in vitro assay. 50So, bl, Akt1, Akt2, Akt3, ALK, ALK5, A-Raf, B-Raf, Brk, Btk, Cdk2, CDK4, CDK5, CDK6, CHK1, c-Raf-1, Csk, EGFR, EphA1, EphA2, EphB2, EphB4, Erk2, F ak, FGFR1, FGFR2, FGFR3, FGFR4, Flt1, Flt3, Flt4, Fms, Frk, Fyn, Gsk3α, Gsk3β, HCK, Her2 / Erbb2, Her4 / Erbb4, IGF1R, IKKβ, Irak4, Itk, Jak1, Jak2 It inhibits kinases including, but not limited to, Jak3, Jnk1, Jnk2, Jnk3, Kdr, Kit, Lck, Lyn, MAP2K1, MAP2K2, MAP4K4, MAPKAPK2, Met, Mnk1, MLK1, p38, PDGFRA, PDGFRB, PDPK1, Pim1, Pim2, Pim3, PKCα, PKCβ, PKCθ, Plk1, Pyk2, ROCK1, ROCK2, Ron, Src, Stk6, Syk, TEC, Tie2, TrkA, TrkB, Yes, and Zap70, as well as any variants thereof. For example, polymorphs of compound A can be confirmed in in vitro kinase assays at ICs of 10 μM, 5 μM, 2 μM, 1 μM, 500 nM, 200 nM, 100 nM, 50 nM, 25 nM, 10 nM, 5 nM, or less in the in vitro assay. 50 The compound inhibits kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E variant, B-Raf V600E / T5291 variant, c-Raf-1, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Jnk1, Jnk2, Jnk3, Lck, Lyn, Met, Pim1, Pim2, Pim3, P yk2, Kdr, Src, and Ret, as well as any variants thereof. In some embodiments, polymorphs of compound A inhibit kinases in an in vitro assay at IC50 levels of 10 μM, 5 μM, 2 μM, 1 μM, 500 nM, 200 nM, 100 nM, 50 nM, 25 nM, 10 nM, or less, as confirmed in the in vitro kinase assay. 50It inhibits a kinase selected from the group consisting of A-Raf, B-Raf, B-Raf V600E mutant, B-Raf V600E / T5291 mutant, or c-Raf-1. For example, the polymorph of compound A has an IC in an in vitro assay of 10 μM, 5 μM, 2 μM, 1 μM, 500 nM, 200 nM, 100 nM, 50 nM, 25 nM, 10 nM, 5 nM or less, as confirmed in an in vitro assay. 50 It inhibits a kinase that is B-Raf or a B-Raf V600E mutant.
[0113] In some embodiments, the polymorph of compound A has an IC in an in vitro assay of 1 μM, 500 nM, 200 nM, 100 nM, 50 nM, 25 nM, 10 nM, 5 nM, or less, as confirmed in an in vitro kinase assay. 50 It inhibits the activity of one or more kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E mutant, B-Raf V600E / T5291 mutant, and c-Raf-1.
[0114] In some embodiments, polymorphs of compound A are Abl, Akt1, Akt2, Akt3, ALK, ALK5, A-Raf, B-Raf, Brk, Btk, Cdk2, CDK4, CDK5, CDK6, CHK1, c-Raf-1, Csk, EGFR, EphA1, EphA2, EphB2, EphB4, Erk2, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Flt1, Flt3, Flt4, Fms, Frk, F It selectively inhibits the activity of one or more kinases selected from the group consisting of yn, Gsk3α, Gsk3β, HCK, Her2 / Erbb2, Her4 / Erbb4, IGF1R, IKKβ, Irak4, Itk, Jak1, Jak2, Jak3, Jnk1, Jnk2, Jnk3, Kdr, Kit, Lck, Lyn, MAP2K1, MAP2K2, MAP4K4, MAPKAPK2, Met, Mnk1, MLK1, p38, PDGFRA, PDGFRB, PDPK1, Pim1, Pim2, Pim3, PKC α, PKC β, PKC θ, Plk1, Pyk2, ROCK1, ROCK2, Ron, Src, Stk6, Syk, TEC, Tie2, TrkA, TrkB, Yes, and Zap70, including all their variants.
[0115] For example, polymorphs of compound A selectively inhibit the activity of one or more kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E mutant, B-Raf V600E / T5291 mutant, c-Raf-1, Fak, FGFR1, FGFR2, FGFR3, FGFR4, Jnk1, Jnk2, Jnk3, Lck, Lyn, Met, Pim1, Pim2, Pim3, Pyk2, Kdr, Src, and Ret. In some embodiments, polymorphs of compound A selectively inhibit the activity of one or more kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E mutant, B-Raf V600E / T5291 mutant, and c-Raf-1.
[0116] In some embodiments, polymorphs of compound A include ABL1, AKT1 (PKBα), AURKB (Aurora B), BLK, BTK, CDK1 / Cyclone B, CHEK1 (CHK1), CSF1R (FMS), CSNK1G2 (CK1γ2), EGFR (ErbB1), FGFR1, FGR, FLT3, FRAP1 (mTOR), FYN, IGF1R, IKBKB (IKKβ), INSR, KDR (VEGFR2), KIT, LCK, LYNA, MAP2K1 (MEK1), MAP4K5 (KHS1), MAPK1 (ERK2), MAPK14 (p38α) ), MAPKAPK2, MET(cMet), PDGFRB(PDGFRβ), PIK3CA / PIK3R1(p110α / p85α)PRKCB2(PKCβII), PTK2B(FAK2), PTK6(Brk), RAF1(cRAF), Y340D, Y341D, RET, RPS6KB1(p70S6K), SRC, SRMS(Srm), and YES1 selectively inhibit the activity of B-Raf or B-Raf V600E variants. In some embodiments, polymorphs of compound A are ABL1, AKT1(PKBα), AURKB(Aurora B), BLK, BTK, CDK1 / Cyclin B, CHEK1(CHK1), CSF1R(FMS), CSNK1G2(CK1gamma2), EGFR(ErbB1), FGFR1, FGR, FLT3, FRAP1(mTOR), FYN, IGF1R, IKBKB(IKKβ), INSR, KDR(VEGFR2), KIT, LCK, LYNA, MAP 2K1(MEK1)MAP4K5(KHS1), MAPK1(ERK2), MAPK14(p38α), MAPKAPK2, MET(cMet), PDGFRB(PDGFRβ ), PIK3CA / PIK3R1(p110α / p85α)PRKCB2(PKCβII), PTK2B(FAK2), PTK6(Brk), RAF1(cRAF)Y340D IC10 for one or more kinases selected from the group consisting of Y341D, RET, RPS6KB1 (p70S6K), SRC, SRMS (Srm), and YES1. 50ICs that are 1 / 2, 1 / 3, 1 / 4, 1 / 5, 1 / 7, 1 / 10, 1 / 15, 1 / 20, 1 / 25, 1 / 30, 1 / 40, 1 / 50, 1 / 100, 1 / 150, 1 / 200, 1 / 300, 1 / 400, 1 / 500, 1 / 1000, 1 / 2000, or less than that. 50 Then, the activity of one or more kinases selected from the group consisting of A-Raf, B-Raf, B-Raf V600E mutant, B-Raf V600E / T5291 mutant, and c-Raf-1 is inhibited.
[0117] In some embodiments, one or more polymorphs of compound A have the ability to inhibit cell proliferation. For example, in some cases, one or more polymorphs of compound A inhibit the proliferation of tumor cells or tumor cell lines. For example, such cell lines express kinases that are B-raf or B-raf V600E variants. In some cases, one or more polymorphs of compound A inhibit the proliferation of A375 or SK-MEL-28 cells in in vitro or in vivo models such as xenograft mouse models. In some cases, the proliferation of A375 or SK-MEL-28 cells cultured in vitro is inhibited by one or more polymorphs of compound A to IC100nM, 75nM, 50nM, 25nM, 15nM, 10nM, 5nM, 3nM, 2nM, 1nM, 0.5nM, 0.1nM, or less IC10. 50 This can be inhibited.
[0118] V. How to use The polymorphs described herein are useful in treatment or in the preparation of agents for the treatment of various disorders. For example, polymorphs of compound A are useful as inhibitors of protein kinases. In some embodiments, the polymorphs described herein are inhibitors of one or more kinases. For example, polymorphs of compound A are inhibitors of such kinase variants, including A-Raf, B-Raf, C-Raf, and B-Raf V600E variant. Thus, without wishing to be bound by any particular theory, polymorphs of compound A are particularly useful for treating or mitigating the severity of diseases, illnesses, or disorders in which the activation of one or more kinases, such as Raf kinase, is involved. When the activation of Raf kinase is involved in a particular disease, illness, or disorder, that disease, illness, or disorder may also be called a “Raf-mediated disease” or disease symptom. Therefore, in another embodiment, the present invention provides a method for treating or mitigating the severity of diseases, illnesses, or disorders in which the activation of one or more Raf kinases is involved in the disease state.
[0119] Raf kinase inhibition can be assayed in vitro, in vivo, or in cell lines. In vitro assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of activated Raf kinase. Alternative in vitro assays quantify the ability of an inhibitor to bind to Raf kinase. Inhibitor binding can be measured by radiolabeling the inhibitor before binding, isolating the inhibitor and complex, and determining the amount of radiolabeled material bound. Alternatively, inhibitor binding can be determined by performing competitive experiments in which a novel inhibitor is cultured with Raf kinase bound to a known radioligand.
[0120] The polymorphs described herein can typically be prepared in substantially pure form by standard chromatography before being formulated into pharmaceutically acceptable forms.
[0121] The polymorphs described herein may be used in treating various neoplasms, including malignant and benign tumors, as well as cancer. Cancers that can be prevented and / or treated by the polymorphs, compositions, and methods described herein include human sarcomas and carcinomas, e.g., carcinomas such as colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma, vascular sarcoma, endosarcoma, lymphangiosarcoma, lymphangiosarcoma, synovial tumor, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, liver cancer, cholangiocarcinoma, choriocarcinoma, seminocarcinoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular cancer, lung cancer. This includes, but is not limited to, small cell lung cancer, bladder cancer, epithelial cancer, glioma, astrocytic cancer, medulloblastoma, craniopharyngioma, ependymoma, pineal glandoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), leukemia, such as acute lymphoblastic leukemia and acute myeloid leukemia (myeloblastic, promyelocytic, myelomonocytic, and erythroleukemia), chronic leukemia (chronic myeloid (granulocytic) leukemia and chronic lymphocytic leukemia), and polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenström macroglobulinemia, and heavy chain disease. Benign tumors that can be prevented and / or treated by the polymorphs, compositions, and methods described herein include, but are not limited to, craniopharyngiomas.
[0122] In some embodiments, the polymorphs described herein are i. The digestive system, including but not limited to the esophagus, stomach, small intestine, colon (including colorectum), liver and intrahepatic bile ducts, gallbladder and other bile ducts, pancreas, and other digestive organs. ii. The respiratory system, including but not limited to the larynx, lungs and bronchi, and other respiratory organs. iii.Skin, iv. Thyroid gland, v. Breast, vi. The reproductive system, including but not limited to the cervix, ovaries, and prostate gland. vii. The urinary system, including but not limited to the bladder, kidneys, and renal pelvis. Furthermore viii. The oral cavity and pharynx, including but not limited to the tongue, mouth, pharynx, and other oral cavity parts. It is used for the treatment of cancer.
[0123] In some embodiments, the polymorphs described herein are used in the treatment of colon cancer, liver cancer, lung cancer, melanoma, thyroid cancer, breast cancer, ovarian cancer, and oral cancer.
[0124] The polymorphs described herein may also be used in combination with other well-known therapeutic agents selected for their specific utility against the disease being treated. For example, the polymorphs described herein may be useful in combination with at least one additional anticancer agent and / or cytotoxic agent. Furthermore, the polymorphs described herein may also be useful in combination with other inhibitors of the signaling pathway that links cell surface growth factor receptors to nuclear signals that initiate cell proliferation.
[0125] Such known anticancer agents and / or cytotoxic agents that may be used in combination with the polymorphs described herein are: (i) Alkylating agents (e.g., cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan, temozolomide, and nitrosourea), antimetabolites (e.g., gemcitabine, as well as fluoropyrimidines such as 5-fluorouracil and tegafur, folate antimetabolites such as larcitrexed, methotrexate, cytosine arabinoside, and hydroxyurea), antitumor antibiotics (e.g., anthracyclines such as adriamycin, bleomycin, doxorubicin) Other antiproliferative / antitemocyte drugs used in medical oncology and combinations thereof, such as daunorubicin, epirubicin, idarubicin, mitomycin C, dactinomycin, and mitramycin), antimitotic agents (e.g., vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine, as well as taxoids such as taxol and taxotere, and polokinase inhibitors), and topoisomerase inhibitors (e.g., epipodophyllotoxin such as etoposide and teniposide, amsacrin, topotecan, and camptothecin), (ii) Cell proliferation inhibitors, anti-estrogens (e.g., tamoxifen, fulvestrant, toremifene, raloxifene, doroxifene and iodoxifene), anti-androgens (e.g., bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (e.g., goserelin, leuprorelin and buserelin), progestogens (e.g., megestrol acetate), aromatase inhibitors (e.g., anastrozole, letrozole, borazole and exemestane), and 5α-reductase inhibitors such as finasteride. (iii) Anti-soiling agents [e.g., 4-(6-chloro-2,3-methylenedioxyaniline)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530) International patent application WO01 / 94341), c-Src kinase family inhibitors such as N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidine-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J.Med.Chern., 2004, 47, 66586661) and bosutinib (such as SK1-606), as well as metalloproteinase inhibitors such as marimastat and inhibitors of antibodies against the function of urokinase plasminogen activator receptor or heparanase, (iv) Inhibitors of growth factor function For example, such inhibitors include growth factor antibodies and growth factor receptor antibodies (e.g., anti-erbB2 antibody trastuzumab [Herceptin®], anti-EGFR antibody panitumumab, anti-erbB1 antibody cetuximab [Erbitux, C225], and Stem et al. Critical reviews in oncology / haematology, 2005, Vol. 54, pp This includes any growth factor or growth factor receptor antibody disclosed in 11-29, and such inhibitors include tyrosine kinase inhibitors, e.g., inhibitors of the epidermal growth factor family (e.g., EGFR family tyrosine kinase inhibitors, e.g., N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazoline-4-amine (gefitinib, ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazoline-4-amine (erlotinib, OSI-774), and 6-A Crillamide-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazoline-4-amine (CI1033, erbB2 tyrosine kinase inhibitors such as lapatinib), hepatocyte growth factor family inhibitors, insulin growth factor family inhibitors, platelet-derived growth factor family inhibitors such as imatinib and / or nilotinib (AMN107), serine / threonine kinase inhibitors (e.g., Ras / Raf signaling inhibitors such as farnesyltransferase inhibitors, e.g., sorafenib (BAY) 43-9006), tipifarnib (RI15777) and ronafarnib (SCH66336), inhibitors of cell signaling mediated by MEK and / or AKT kinases, c-kit inhibitors, abl kinase inhibitors, P13 kinase inhibitors, Plt3 kinase inhibitors, CSF-IR kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors, Aurora kinase inhibitors (e.g., AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528, and AX39459). Also included are cyclin-dependent kinase inhibitors such as CDK2 and / or CDK4 inhibitors. (v) Anti-angiogenic agents that inhibit the effects of vascular endothelial growth factor [e.g., the anti-vascular endothelial growth factor antibody bevacizumab (Avastin®), and e.g., vandetanib (ZD6474), batalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), pazopanib (GW 786034), and 4·{4-fluoro-2-methylindole-5-yloxy)-6-methoxy-7-(3-pyrrolidine-1-ylpropoxy)quinazoline) (AZD2171 VEGF receptor tyrosine kinase inhibitors such as Example 240 in WO00 / 47212, compounds such as those disclosed in international patent applications WO97 / 22596, WO97 / 30035, WO97 / 32856, and WO98 / 13354, as well as compounds acting by other mechanisms (e.g., linamide, integrin αv-3 function inhibitors, and angiostatins), (vi) Vascular damage agents such as combretastatin A4 and compounds disclosed in international patent applications WO99 / 02166, WO00 / 40529, WO00 / 41669, WO01 / 92224, WO02 / 04434 and WO02 / 08213, (vii) Endothelin receptor antagonists, e.g., dibotentan (ZD4054) or atrasentan, (viii) Antisense therapies, such as ISIS2503 and antiras antisense, which are directed at the aforementioned targets. (ix) Gene therapy approaches including approaches to replace abnormal genes such as abnormal p53 or abnormal BRCA1 or BRCA2, GDEPT (gene-directed enzyme prodrug therapy) approaches such as approaches using cytosine deaminase, thymidine kinase or bacterial nitroreductase enzymes, and approaches to increase the resistance of a target to chemotherapy or radiotherapy, such as multidrug resistance gene therapy. (x) Immunotherapy approaches including, for example, ex vivo and in vivo approaches to increase the immunogenicity of target tumor cells, such as transfection with cytokines like interleukin-2, interleukin-4, or granulocyte-macrophage colony-stimulating factor; approaches to reduce T cell energy; approaches using transfected immune cells such as cytokine-transfected dendritic cells; approaches using cytokine-transfected tumor cell lines; and approaches using anti-idiotype antibodies. Includes.
[0126] In certain embodiments, at least one polymorph of compound A is administered in combination with one or more agents selected from paclitaxel, bortezomib, dacarbazine, gemcitabine, trastuzumab, bevacizumab, capecitabine, docetaxel, erlotinib, aromatase inhibitors such as AROMASIN® (exemestane), and estrogen receptor inhibitors such as FASLODEX® (fulvestrant).
[0127] When polymorphs of compound A are administered to human subjects, the dose may be determined by the prescribing physician, and is generally a variable dose depending on the age, weight, and response of the individual subject, as well as the severity of the subject's symptoms.
[0128] In one exemplary application, an appropriate amount of at least one polymorph of compound A is administered to a mammal undergoing treatment for cancer, such as breast cancer. The administration is generally in amounts between approximately 0.01 mg / kg and approximately 100 mg / kg of body weight per day, such as at least approximately 0.1 mg / kg of body weight per day (administered as a single dose or in divided doses). Specific therapeutic doses may include, for example, approximately 0.01 mg to approximately 1000 mg of polymorphs of compound A, or, for example, approximately 1 mg to approximately 1000 mg. The amount of at least one polymorph of compound A in a unit dose of a preparation may vary or be adjusted between approximately 0.1 mg and 1000 mg, and depending on the specific application, may be approximately 1 mg to 300 mg, or, for example, 10 mg to 200 mg. The amount administered is the specific IC of at least one polymorph of compound A used. 50 The values may vary depending on the judgment of the attending clinician, taking into account factors such as health, weight, and age. In combination applications where at least one polymorph of compound A described herein is not the sole active ingredient, it may still be possible to administer a smaller amount of at least one polymorph of compound A while still having a therapeutic or preventive effect.
[0129] In some embodiments, the preparation of the drug is in the form of a unit dosage form. In such forms, the preparation is subdivided into unit doses containing an appropriate amount of polymorphs of compound A, for example, an effective amount to achieve the desired purpose.
[0130] The actual dose used may vary depending on the requirements of the subject and the severity of the disease being treated. Determining the appropriate dose for a particular situation is within the scope of the art. Generally, treatment is initiated with a dose less than the optimal dose of at least one polymorph of compound A. Thereafter, the dose is increased in small increments until the optimal effect is achieved under the given circumstances. For convenience, the total daily dose may be divided and administered in several portions throughout the day, if necessary.
[0131] The dosage and frequency of administration of at least one polymorph of compound A, and, where applicable, other chemotherapeutic agents and / or radiotherapy, will be adjusted at the discretion of the attending clinician (physician), taking into account factors such as the patient's age, disease and size, and the severity of the disease being treated.
[0132] Chemotherapy agents and / or radiotherapy can be administered according to treatment protocols well known in the art. It will be apparent to those skilled in the art that the administration of chemotherapeutic agents and / or radiotherapy may vary depending on the disease being treated and the known effects of the chemotherapeutic agents and / or radiotherapy on that disease. Furthermore, in accordance with the knowledge of a skilled clinician, treatment protocols (e.g., dosage and administration timing) may be modified in consideration of the observed effects of the administered therapeutic agent (i.e., antitumor agent or radiation) on the subject and the observed response of the disease to the administered therapeutic agent.
[0133] Furthermore, generally, at least one polymorph of compound A does not need to be administered in the same pharmaceutical composition as the chemotherapeutic agent, and may be administered by different routes due to their different physical and chemical properties. For example, the polymorph / composition may be administered orally to produce and maintain its good blood levels, while the chemotherapeutic agent may be administered intravenously. Where possible, the determination of the method of administration and the appropriateness of administration in the same pharmaceutical composition may be within the scope of the knowledge of a skilled clinician. The initial administration may be carried out according to established protocols known in the art, and then, based on the observed effects, the dosage, method of administration, and timing of administration may be modified by a skilled clinician.
[0134] The specific selection of polymorphs (and, where appropriate, chemotherapy agents and / or radiation) depends on the attending physician's diagnosis, assessment of the disease, and appropriate treatment protocol.
[0135] One or more polymorphs of compound A (and, where appropriate, chemotherapeutic agents and / or radiation) may be administered simultaneously (e.g., simultaneously, essentially simultaneously, or within the same treatment protocol) or sequentially, depending on the nature of the proliferative disorder, the disease of interest, and the actual selection of chemotherapeutic agents and / or radiation administered in conjunction with one or more polymorphs / compositions (i.e., within a single treatment protocol).
[0136] In concomitant applications and uses, one or more polymorphs / compositions, as well as chemotherapeutic agents and / or radiation, do not need to be administered simultaneously or essentially simultaneously, and the initial order of administration of one or more polymorphs / compositions, as well as chemotherapeutic agents and / or radiation, may not be important. Thus, at least one polymorph of compound A may be administered first, followed by chemotherapeutic agents and / or radiation, or the chemotherapeutic agents and / or radiation may be administered first, followed by at least one polymorph of compound A. This alternative administration may be repeated within a single treatment protocol. The determination of the order of administration and the number of repetitions of each therapeutic agent in the treatment protocol may be within the knowledge of a skilled physician after evaluating the disease being treated and the target disease. For example, chemotherapeutic agents and / or radiation may be administered first, and then the treatment may continue with administration of at least one polymorph of compound A, followed by chemotherapeutic agents and / or radiation, etc., if it is determined to be advantageous, until the treatment protocol is completed.
[0137] Therefore, in accordance with experience and knowledge, the attending physician may modify each protocol for the administration of polymorphs of compound A / composition for treatment according to the needs of the individual patient as the treatment progresses.
[0138] The attending clinician will consider the patient's overall health status, as well as more pronounced signs such as reduction of disease-related symptoms, inhibition of tumor growth, actual tumor shrinkage, or inhibition of metastasis, when determining whether the treatment is effective at the administered dosage. Tumor size can be measured by standard radiological studies, such as CAT or MRI scans, and continuous measurements can be used to determine whether tumor growth has been delayed or reversed. Reduction of disease-related symptoms such as pain and overall improvement of the disease can also be used to help determine the effectiveness of the treatment. VI. Compositions and Formulations
[0139] This disclosure provides compositions comprising a pharmaceutical composition containing one or more crystalline forms of the present invention.
[0140] In various embodiments, the ratio of a desired crystalline form, such as crystalline form 1, to all other crystalline forms in the composition is greater than approximately 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or more than w / w. In other embodiments, the ratio of crystalline form II to all other polymorphs is greater than approximately 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, or more than w / w.
[0141] In some embodiments, one or more polymorphs of compound A are formulated into a pharmaceutical composition. In certain embodiments, the pharmaceutical composition is formulated in a conventional manner using one or more physiologically acceptable carriers, which include excipients and adjuvants that facilitate the processing of the active compound / polymorph into a pharmaceutically usable preparation. The appropriate formulation varies depending on the selected route of administration. Any pharmaceutically acceptable techniques, carriers, and excipients may be used as appropriate for formulating the pharmaceutical compositions described herein: Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).
[0142] Provided herein are pharmaceutical compositions comprising one or more polymorphs of compound A and pharmaceutically acceptable diluents(s), excipients(s), or carriers(s). In certain embodiments, one or more polymorphs of compound A are administered as a pharmaceutical composition in which one or more polymorphs are mixed with other active ingredients, as in combination therapy. Included herein are the following paragraphs on combination therapy and all combinations of active substances described throughout this disclosure. In certain embodiments, the pharmaceutical composition comprises one or more polymorphs of compound A.
[0143] When used herein, a pharmaceutical composition refers to a mixture of one or more polymorphs of compound A and other chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. In certain embodiments, the pharmaceutical composition facilitates the administration of the polymorphs to an organism. In some embodiments, when carrying out a therapeutic method or method of use provided herein, a therapeutically effective amount of one or more polymorphs of compound A, in the pharmaceutical composition, is administered to a mammal having the disease or illness being treated. In certain embodiments, the mammal is a human. In certain embodiments, the therapeutically effective amount varies depending on the severity of the disease, the age and relative health status of the subject, and other factors. One or more polymorphs of compound A described herein are used as components of a mixture, alone, or in combination with one or more therapeutic agents.
[0144] In one embodiment, one or more polymorphs of compound A are formulated in an aqueous solution. In certain embodiments, the aqueous solution is selected from, for example, a physiologically compatible buffer, Hanks' solution, Ringer's solution, or physiological saline buffer. In other embodiments, one or more polymorphs of compound A are formulated for transmucosal administration. In certain embodiments, the transmucosal formulation includes a suitable permeation agent for the barrier to which it is permeated. In yet another embodiment, in which one or more polymorphs described herein are formulated for other parenteral injections, the suitable formulation includes an aqueous solution or a non-aqueous solution. In certain embodiments, such a solution includes a physiologically compatible buffer and / or excipients.
[0145] In another embodiment, the polymorphs described herein are formulated for oral administration. The polymorphs of compound A are formulated by combining the polymorphs with, for example, pharmaceutically acceptable carriers or excipients. In various embodiments, the polymorphs described herein are formulated into oral dosage forms, including, but not limited to, tablets, powders, pills, sugars, capsules, liquids, gels, syrups, elixirs, slurries, suspensions, and the like.
[0146] In certain embodiments, pharmaceutical preparations for oral use are obtained by mixing one or more solid excipients with one or more polymorphs described herein, optionally grinding the resulting mixture, and processing the granular mixture after adding suitable auxiliary agents as desired to obtain tablets or sugar preparations. Suitable excipients are, specifically, fillers such as sugars containing lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, microcrystalline cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, or others such as polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. In certain embodiments, disintegrants are optionally added. Disintegrants include, just a few examples, cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid, or salts thereof such as sodium alginate.
[0147] In one embodiment, dosage forms such as sugar cores and tablets are provided with one or more suitable coatings. In certain embodiments, a concentrated sugar solution is used to coat the dosage form. The sugar solution optionally contains additional components such as gum arabic, talc, polyvinylpyrrolidone, Carbopol gel, polyethylene glycol, and / or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures, just as examples. Dyes and / or pigments are also optionally added to the coating for identification purposes. Furthermore, dyes and / or pigments are optionally used to characterize different combinations of active compound doses.
[0148] In certain embodiments, at least one therapeutically effective amount of the polymorphs described herein is formulated into other oral dosage forms. These oral dosage forms include push-fit capsules made of gelatin, as well as soft-seal capsules made of gelatin and a plasticizer such as glycerol or sorbitol. In certain embodiments, the push-fit capsules contain the active ingredient in a mixture with one or more fillers. Fillers include, but are not limited to, binders such as lactose or starch, and / or lubricants such as talc or magnesium stearate, and optionally stabilizers. In other embodiments, the soft capsules contain one or more active compounds dissolved or suspended in a suitable liquid. Suitable liquids include, but are not limited to, one or more fatty oils, liquid paraffins, or liquid polyethylene glycol. Further stabilizers are optionally added.
[0149] In other embodiments, at least one therapeutically effective dose of the polymorphs described herein is formulated for buccal or sublingual administration. Formulations suitable for buccal or sublingual administration include, but are not limited to, tablets, lozenges, or gels. In yet another embodiment, the polymorphs described herein are formulated for parenteral injection, including formulations suitable for bolus injection or continuous infusion. In certain embodiments, formulations for injection are presented in unit dosage forms (e.g., in ampoules) or in multi-dose containers. Preservatives are optionally added to the injectable formulation. In yet another embodiment, the pharmaceutical composition of the polymorph of compound A is formulated in a form suitable for parenteral injection as a sterile suspension, solution, or emulsion in an oily or aqueous vehicle. The parenteral injection formulation optionally contains formulation agents such as suspending agents, stabilizers, and / or dispersants. In certain embodiments, the pharmaceutical formulation for parenteral administration comprises an aqueous solution of the active polymorph in a water-soluble form. In further embodiments, the suspension of the active polymorph is prepared as a suitable oily injection suspension. Suitable lipophilic solvents or vehicles for use in the pharmaceutical compositions described herein include, to name just a few, fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. In certain embodiments, the aqueous injection suspension contains a substance that increases the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension contains a suitable stabilizer or agent that increases the solubility of the polymorph, enabling the preparation of high-concentration solutions. Alternatively, in other embodiments, the active ingredient is in powder form for use with a suitable vehicle, such as sterile water free of pyrogens, before use.
[0150] In yet another embodiment, one or more polymorphs of compound A are administered topically. One or more polymorphs described herein are formulated into various topically administerable compositions such as solutions, suspensions, lotions, gels, pastes, medicinal sticks, balms, creams, or ointments. Such pharmaceutical compositions optionally contain solubilizers, stabilizers, isotonic enhancers, buffers, and preservatives.
[0151] In further embodiments, one or more polymorphs of compound A are formulated for transdermal administration. In certain embodiments, the transdermal formulation may be a lipophilic emulsion or buffered aqueous solution dissolved and / or dispersed in a polymer or adhesive, using transdermal delivery devices and transdermal delivery patches. In various embodiments, such patches are configured for continuous, pulsed, or on-demand delivery of the drug. In further embodiments, transdermal delivery of one or more polymorphs of compound A is achieved by means such as iontophoresis patches. In certain embodiments, the transdermal patch provides controlled delivery of one or more polymorphs of compound A. In certain embodiments, the absorption rate is slowed by using a rate-controlled membrane or by trapping the compound within a polymer matrix or gel. In alternative embodiments, absorption enhancers are used to increase absorption. The absorption enhancer or carrier contains an absorbable, pharmaceutically acceptable solvent that helps it pass through the skin. For example, in one embodiment, the transdermal device is in the form of a bandage comprising a backing member, optionally a reservoir containing the compound together with a carrier, optionally a rate-controlled barrier for delivering the compound to the host skin at a predetermined controlled rate over a long period of time, and means for securing the device to the skin.
[0152] In other embodiments, one or more polymorphs of compound A are formulated for administration by inhalation. Various forms suitable for administration by inhalation include, but are not limited to, aerosols, mists, or powders. Pharmaceutical compositions of polymorphs of compound A are conveniently delivered in the form of aerosol spray presentation from a pressurized pack or nebulizer, using a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas). In certain embodiments, the dosage unit of the pressurized aerosol is determined by providing a valve for delivering a measured amount. In certain embodiments, as merely an example, capsules and cartridges, such as gelatin, for use in inhalers or injectors are formulated to contain a powder mixture of the compound and a suitable powder base, such as lactose or starch.
[0153] In further embodiments, one or more polymorphs of compound A are formulated into rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retained enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone and PEG. In the suppository form of the composition, a low-melting-point wax, such as a mixture of fatty acid glycerides, is optionally melted first in combination with cocoa butter.
[0154] In certain embodiments, the pharmaceutical composition is formulated in any conventional manner using one or more physiologically acceptable carriers, including excipients and adjuvants that facilitate the processing of the active polymorphs into pharmaceutically usable preparations. The appropriate formulation depends on the chosen route of administration. Any pharmaceutically acceptable techniques, carriers, and excipients are used as appropriate at any discretion. Pharmaceutical compositions comprising one or more polymorphs of compound A are produced, as merely an example, by conventional methods such as conventional mixing, dissolution, granulation, sugar preparation, polishing, emulsification, encapsulation, encapsulation, or compression processes.
[0155] A pharmaceutical composition comprises at least one pharmaceutically acceptable carrier, diluent, or excipient, and at least one polymorph of compound A described herein as an active ingredient. The active ingredient is in the form of a free acid or free base, or a pharmaceutically acceptable salt. All tautomers of the compounds described herein fall within the range of compounds presented herein. Furthermore, the compounds described herein encompass both non-solvated forms and solvated forms with pharmaceutically acceptable solvents such as water and ethanol. The solvated forms of the compounds presented herein are also considered to be disclosed herein. In addition, a pharmaceutical composition may optionally include other medical or pharmaceutical products, carriers, preservatives, stabilizers, wetting agents or emulsifiers, adjuvants, dissolution accelerators, salts for adjusting osmotic pressure, buffers, and / or other therapeutically valuable substances.
[0156] A method for preparing a composition comprising one or more polymorphs of compound A as described herein comprises formulating the polymorphs using one or more inert, pharmaceutically acceptable excipients or carriers to form a solid, semi-solid, or liquid. Solid compositions include, but are not limited to, powders, tablets, granular wettable powders, capsules, cachets, and suppositories. Liquid compositions include solutions in which the compound is dissolved, emulsions containing the compound, or solutions containing liposomes, micelles, or nanoparticles containing the compound, as disclosed herein. Semi-solid compositions include, but are not limited to, gels, suspensions, and creams. The forms of pharmaceutical compositions described herein include liquid solutions or suspensions, solid forms suitable for solutions or suspensions in liquids before use, or emulsions. These compositions also optionally contain small amounts of non-toxic auxiliary substances, such as wetting agents or emulsifiers or pH buffers.
[0157] In some embodiments, the pharmaceutical composition comprising at least one polymorph of compound A takes an exemplary liquid form, and the drug exists in a solution, a suspension, or both. Generally, when the composition is administered as a solution or suspension, a first portion of the drug exists in the solution, and a second portion of the drug exists in particulate form in a suspension within a liquid matrix. In some embodiments, the liquid composition comprises a gel formulation. In other embodiments, the liquid composition is aqueous.
[0158] In certain embodiments, a useful aqueous suspension contains one or more polymers as a suspending agent. Useful polymers include water-soluble polymers such as cellulose polymers, water-insoluble polymers such as hydroxypropyl methylcellulose, and crosslinked carboxyl-containing polymers. Specific pharmaceutical compositions described herein include, for example, mucosal-adhering polymers selected from carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methyl methacrylate), polyacrylamide, polycarbophil, acrylic acid / butyl acrylate copolymer, sodium alginate, and dextran.
[0159] Useful pharmaceutical compositions may further optionally include a solubilizer to assist the solubility of polymorphs of compound A. The term “solubilizer” generally includes agents that result in the formation of micelle or true solutions of the drug. Certain acceptable nonionic surfactants, such as polysorbate 80, ophthalmologically acceptable glycols, polyglycols, such as polyethylene glycol 400, and glycol ethers are useful as solubilizers.
[0160] Furthermore, useful pharmaceutical compositions optionally include one or more pH adjusters or buffers, including acids such as acetic acid, boric acid, citric acid, lactic acid, phosphoric acid, and hydrochloric acid; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, and tris-hydroxymethylaminomethane; and buffers such as citrate / dextrose, sodium bicarbonate, and ammonium chloride. Such acids, bases, and buffers are included in amounts necessary to maintain the pH of the composition within an acceptable range.
[0161] Furthermore, a useful composition may optionally further include one or more salts in amounts necessary to bring the weight osmolality of the composition into an acceptable range. Suitable salts include those having sodium, potassium or ammonium cations and chlorides, citric acid, ascorbic acid, boric acid, phosphoric acid, bicarbonate, sulfates, thiosulfates, or bisulfite anions, and such salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite, and ammonium sulfate.
[0162] Other useful pharmaceutical compositions optionally include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal, stabilized chlorine dioxide, and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide, and cetylpyridinium chloride.
[0163] Furthermore, other useful compositions may contain one or more surfactants to enhance physical stability or for other purposes. Suitable nonionic surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, such as polyoxyethylene (60) hydrogenated castor oil, as well as polyoxyethylene alkyl ethers and alkylphenyl ethers, such as octoxynol 10 and octoxynol 40.
[0164] Furthermore, other useful compositions may include one or more antioxidants to enhance chemical stability, if necessary. Suitable antioxidants include, but are not limited to, ascorbic acid and sodium pyrosulfite.
[0165] In certain embodiments, the aqueous suspension composition is packaged in a single-dose, non-resealable container. Alternatively, resealable containers for multiple doses are used when it is common for the composition to contain preservatives.
[0166] In alternative embodiments, other delivery systems for hydrophobic pharmaceutical compounds are used. Liposomes and emulsions are examples of useful delivery vehicles or carriers herein. In certain embodiments, organic solvents such as N-methylpyrrolidone are also used. In further embodiments, the polymorphs described herein are delivered using sustained-release systems such as a semipermeable matrix of a solid hydrophobic polymer containing the therapeutic agent. Various sustained-release materials are useful herein. In some embodiments, sustained-release capsules release the polymorphs for several weeks to over 100 days. Depending on the chemical properties and biological stability of the therapeutic reagent, further strategies for protein stabilization are used.
[0167] In certain embodiments, the formulations described herein include one or more antioxidants, metal chelating agents, thiol-containing compounds, and / or other common stabilizers. Examples of such stabilizers include, but are not limited to, (a) glycerol at approximately 0.5% to 2% w / v, (b) methionine at approximately 0.1% to 1% w / v, (c) monothioglycerol at approximately 0.1% to 2% w / v, (d) EDTA at approximately 1 mM to 10 mM, (e) ascorbic acid at approximately 0.01% to 2% w / v, (f) polysorbate 80 at 0.003% to 0.02% w / v, (g) polysorbate 20 at 0.001% to 0.05% w / v, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrin, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc, or (n) combinations thereof.
[0168] VII. Route of administration Appropriate routes of administration include, but are not limited to, oral, intravenous, rectal, aerosol, parenteral, ocular, pulmonary, transmucosal, transdermal, vaginal, ear, nasal, and topical administration. Furthermore, as merely an example, parenteral delivery includes intramuscular, subcutaneous, intravenous, intrathecal injection, as well as intrathecal, direct intraventricular, intraperitoneal, intralymphatic, and intranasal injection.
[0169] In one embodiment, the polymorph of compound A is administered in a topical rather than systemic manner, for example, by direct injection of the polymorph into an organ, often in a depot preparation or sustained-release formulation. In certain embodiments, long-acting formulations are administered by implantation (e.g., subcutaneous or intramuscular) or intramuscular injection. Furthermore, in other embodiments, the drug is delivered in a targeted drug delivery system, for example, in liposomes coated with an organ-specific antibody. In such embodiments, the liposomes target an organ and are selectively taken up by that organ. In yet another embodiment, the polymorph of compound A is provided in the form of an immediate-release formulation, an extended-release formulation, or an intermediate-release formulation. In yet another embodiment, the polymorph of compound A is administered topically.
[0170] VIII. Kits / Products Kits and products are also provided for use in the therapeutic applications described herein. In some embodiments, such kits include a carrier, package, or container partitioned to receive one or more containers, such as vials, tubes, etc., and each of the containers(s) includes one of the separate elements used in the manner described herein. Suitable containers include, for example, bottles, vials, syringes, and test tubes. Containers are formed from a variety of materials, such as glass or plastic.
[0171] Products provided herein include packaging materials. Packaging materials for use in packaging pharmaceuticals include, for example, those found in U.S. Patents 5,323,907, 5,052,558, and 5,033,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging materials appropriate for selected formulations and the intended mode of administration or treatment. For example, a container(s) optionally contains one or more polymorphs described herein, either in the composition or in combination with another agent disclosed herein. A container(s) optionally has a sterile access port (for example, a container is an intravenous solution bag or vial with a stopper that can be pierced by a subcutaneous needle). Such a kit optionally contains the compound together with a description or label or instructions identifying its use in the methods described herein.
[0172] For example, a kit generally includes one or more additional containers, each containing one or more of the various materials desired from a commercial and user perspective for the use of the compounds described herein (such as reagents, optionally concentrated forms, and / or devices). Non-limiting examples of such materials include, but are not limited to, buffers, diluents, filters, needles, syringes, carriers, packaging, containers, vials, and / or tube labels listing the contents and / or instructions for use, as well as accompanying documentation with instructions for use. A set of instructions for use is also generally included. Labels are optionally on the container or associated with the container. For example, if the letters, numbers, or other characters forming the label are attached, molded, or etched onto the container itself, the label is on the container; as well as associated with the container if the label is present within the receptacle or carrier holding the container, for example, as accompanying documentation. Furthermore, labels are used to indicate that the contents will be used for a specific therapeutic purpose. Additionally, labels indicate instructions for the use of the contents in the methods described herein, etc. In certain embodiments, the pharmaceutical composition is provided in a pack or dispenser device containing one or more unit dosage forms containing the compounds provided herein. The pack includes, for example, metal or plastic foil such as a blister pack. Alternatively, the pack or dispenser device is accompanied by instructions for use for administration. Alternatively, the pack or dispenser is accompanied by a notice related to the container in the form prescribed by the government agency that regulates the manufacture, use, or sale of the pharmaceutical, and this notice reflects agency approval of the form of the drug for human or veterinary administration. Such notice is, for example, a label or approved package insert approved by the U.S. Food and Drug Administration for a prescription drug. In some embodiments, a composition containing polymorphs of compound A formulated in a suitable pharmaceutical carrier is prepared, placed in a suitable container, and labeled for the treatment of the indicated disease. [Examples]
[0173] The following examples serve to more fully illustrate how the present invention is used. These examples are presented for illustrative purposes only and are not intended to limit the true scope of the invention.
[0174] It should be understood that references to specific buffers, media, reagents, cells, culture conditions, etc., when performing the procedures of the methods described herein are not intended to be limiting, but should be read as including all relevant material that a person skilled in the art would find of interest or value in the specific context in which the discussion is presented. For example, it is often possible to substitute one buffer system or culture medium with another and still achieve similar, if not identical, results. A person skilled in the art will have sufficient knowledge of such systems and methods to make substitutions that best serve their purpose when using the methods and procedures disclosed herein without excessive experimentation.
[0175] Example 1. Preparation of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide (Compound A)
[0176] [ka] Process 1 A solution of quinoxaline-2(1H)-one (54.64 g, 374 mmol, 1.0 equivalent) in HOAc (1000 mL) was added dropwise to a solution of Br2 (19.18 mL, 374 mmol, 1.0 equivalent) in HOAc (200 mL). The resulting mixture was stirred at room temperature for 12 hours and then poured into ice water. The precipitate was collected by filtration and dried to obtain 7-bromoquinoxaline-2(1H)-one as an off-white solid (74 g, 88%).
[0177] Process 2 A suspension of 7-bromoquinoxaline-2(1H)-one (224 g, 1 mol, 1.0 equivalent) in POCl3 (1000 mL) was mixed with DMF (3.65 g, 0.05 mol, 0.05 equivalent). The resulting mixture was stirred at 120 °C for 2 hours, then cooled to room temperature and slowly poured into ice water while vigorously stirring. The precipitate was collected by filtration and dried to obtain 7-bromo-2-chloroquinoxaline as a brown solid (180 g, 75%).
[0178] Process 3 To a solution of 7-bromo-2-chloroquinoxaline (50 g, 0.2 mol, 1.0 equivalent) in CH3CN (200 mL), morpholine (89 g, 1.02 mol, 5.0 equivalents) and K2CO3 (85 g, 0.61 mol, 3.0 equivalents) were added. The resulting mixture was stirred at 90°C for 2 hours, then cooled and filtered. The filtrate was concentrated, and the residue was recrystallized from EA to obtain 4-(7-bromoquinoxaline-2-yl)morpholine (59 g, 98.3%).
[0179] Process 4 To a solution of 4-(7-bromoquinoxaline-2-yl)morpholine (59 g, 0.2 mol, 1.0 equivalent) in DMF (500 mL), TEA (139 mL, 1.0 mol, 5.0 equivalent), Et3SiH (127 mL, 0.8 mol, 4.0 equivalent), and Pd(dppf)Cl2·CH2Cl2 (8.16 g, 0.01 mol, 0.05 equivalent) were added. The resulting mixture was stirred in an autoclave under CO (1 MPa) at 90°C for 12 hours, then cooled and concentrated. The resulting residue was purified by flash column chromatography (EA / PE = 1 / 1) to obtain 3-morpholinoquinoxaline-6-carboaldehyde as a yellow solid (40 g, 82.3%).
[0180] Process 5 To 30 mL of THF cooled to -78°C, N-(2,4,5-trifluorophenyl)pivalamide (550 mg, 2.4 mmol, 1.2 equivalents) was added dropwise with LDA (4.1 mL, 4.8 mmol, 2.4 equivalents). The resulting mixture was stirred at -78°C for 1 hour, and then solvent for 3-morpholinoquinoxaline-6-carboaldehyde (486 mg, 2.0 mol, 1.0 equivalent) in 20 mL of THF solution was added dropwise. The resulting mixture was stirred at -78°C for 1 hour, and then quenched by adding NH4Cl solution. The mixture was extracted with EA (20 mL x 3), and the combined organic layers were dried over Na2SO4 and concentrated. The resulting residue was purified by flash column chromatography (MeOH / DCM = 1 / 50, v / v) to obtain N-(2,4,5-trifluoro-3-(hydroxy(3-morpholinoxaline-6-yl)methyl)phenyl) pivalamide (620 mg, 65.2%).
[0181] Process 6 A solution of N-(2,4,5-trifluoro-3-(hydroxy(3-morpholinoquinoxaline-6-yl)methyl)phenyl)pivaramide (620 mg, 1.3 mmol, 1.0 equivalent) in DCM (10 mL) was mixed with MnO2 (358 mg, 6.5 mmol, 5.0 equivalent). The resulting mixture was stirred overnight at 50°C, then cooled and filtered. The filtrate was concentrated, and the residue was purified by flash column chromatography (PE / EA = 1 / 2, v / v) to obtain N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)pivaramide (560 mg, 90%).
[0182] Process 7 A solution of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)pivaramide (560 mg, 1.2 mmol, 1.0 equivalent) in HOAc (10 mL) was mixed with concentrated HCl (50 mL). The mixture was stirred at 110 °C for 4 hours and then poured onto ice. The mixture was adjusted to pH 10 by adding 1N NaOH solution and then extracted with DCM (100 mL x 3). The bound organic layer was dried over Na2SO4 and concentrated. The resulting residue was purified by flash column chromatography (PE / EA = 1 / 4, v / v) to obtain (3-amino-2,5,6-trifluorophenyl)(3-morpholinoquinoxaline-6-yl)methanone as a brown solid (410 mg, yield 88%).
[0183] Process 8 To a solution of (3-amino-2,5,6-trifluorophenyl)(3-morpholinoquinoxaline-6-yl)methanone (40 mg, 0.1 mmol, 1.0 equivalent) in DCM (10 mL), TEA (101 mg, 1 mol, 10 equivalents) and propane-1-sulfonyl chloride (0.5 mL, 0.5 mmol, 5.0 equivalents) were added. The resulting mixture was stirred at room temperature for 1 hour, then washed with water and extracted with DCM (10 mL × 3). The bound organic layer was dried over Na2SO4, filtered, and concentrated. The resulting residue was purified by flash column chromatography (PE / EA = 2 / 1, v / v) to obtain N-(propylsulfonyl)-N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide (41 mg, 62.2%).
[0184] Process 9 A solution of N-(propylsulfonyl)-N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide (41 mg, 0.068 mmol, 1.0 equivalent) in MeOH / THF (10 mL / 10 mL) was mixed with 1N NaOH (0.15 mmol, 2.2 equivalents). The resulting mixture was stirred at room temperature for 1 hour and then concentrated. The resulting residue was purified by flash column chromatography (PE / EA=1 / 1, v / v) to obtain N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide (compound A) (23 mg, 68.9%). The LRMS (M+H) was calculated and confirmed to be 495.1. + )m / z. 1 H NMR (CDCl3, 400MHz) δ8.67(s, 1H), 7.98~8.03(m, 3H), 7.66~7.73(m, 1H), 6.72(s, 1H), 3.78~3.88(m, 8H), 3.12~3.16(t, 2H), 1.87~1.92(q, 2H), 1.05~1.09(t, 3H).
[0185] Example 2. Preparation of crystalline form I of compound A N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide (2.53 kg) and ethyl acetate (EA) (9.1 kg) were added to the reactor. The mixture was stirred under reflux for 2 hours. The solution was cooled to room temperature. The resulting precipitate was filtered, washed with EA (1 kg), and dried under vacuum at 45°C to obtain crystalline form I (1.94 kg, 76.7%) of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide.
[0186] Example 3. Preparation of crystalline form II of compound A N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide (4.01 kg) was dissolved in EA (60 kg), and water (20 kg) was added. The organic phase was separated and concentrated to 4-6 kg under vacuum at 40-45°C. The resulting residue was dissolved in EA (6 kg) and stirred at 10-20°C for 4 hours. The solid was filtered, washed with EA (1.5 kg), and dried under vacuum at 50-55°C to obtain crystalline form II (3.15 kg, 78.6%) of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propan-1-sulfonamide.
[0187] Example 4. X-ray powder diffraction (XRPD) X-ray powder diffraction (XRPD) patterns were obtained using a Shimadzu XRD-6000. A CuK source (=1.54056 angstroms) operating minimally at 40kV and 30mA scanned each sample at 5–50 degrees (2θ). The step size was 0.02 degrees (2θ), and the scanning speed was 1 second per step.
[0188] The XRPD patterns obtained for crystalline form I of compound A are summarized in Table 1 and Figure 1.
[0189] [Table 1]
[0190] The XRPD patterns obtained for crystalline form II of compound A are summarized in Table 2 and Figure 4.
[0191] [Table 2]
[0192] Example 5. Thermogravimetric Analysis (TGA) Thermogravimetric analysis was performed using a TA Instrument TGA unit (NETZSCH TG209). The sample was heated in a platinum pan from ambient temperature to 350°C at 10 K / min. The TGA thermogram obtained for crystalline form I of compound A is summarized in Figure 3.
[0193] Example 6. Differential Scanning Calorimetry (DSC) Differential scanning calorimetry analysis was performed using a TA Instrument DSC unit (METTLER DSC3). Samples were heated from ambient temperature to 300°C in an open aluminum pan at 20 K / min with a nitrogen purge of 50 mL / min. Figure 2 summarizes the DSC thermogram obtained for crystalline form I of compound A. Figure 5 summarizes the DSC thermogram obtained for crystalline form II of compound A.
[0194] Example 7. High-performance liquid chromatography (HPLC) High-performance liquid chromatography (HPLC) was performed using the following equipment and / or conditions.
[0195] [Table 3]
[0196] Example 8. Stability test of crystal morphology I Crystal morphology I remained unchanged after storage at 40°C / 75%RH for 6 months or at 25°C / 60%RH for 6 months. The results for crystal morphology I in accelerated and long-term stability tests are shown in Table 3 and Figures 6-9.
[0197] [Table 4]
[0198] While several embodiments have been shown and described, various modifications and substitutions can be made without departing from the spirit and scope of the invention. For example, for the purpose of constructing the claims, the claims described below are not intended to be interpreted more narrowly than their literal meaning, and therefore, the exemplary embodiments described herein are not intended to be incorporated into the claims. Accordingly, it should be understood that the invention is described as illustrative and not intended to limit the claims.
Claims
1. Crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide (Compound A) [Formula 1] or a pharma- ceutically acceptable solvate or hydrate thereof.
2. Crystalline compound A is crystalline form I, and crystalline form I is (a) an X-ray powder diffraction pattern containing peaks at 8.7±0.2° 2-θ, 21.6±0.2° 2-θ, and 24.4±0.2° 2-θ, as measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å; (b) an X-ray powder diffraction pattern substantially the same as that shown in FIG. (c) a differential scanning calorimetry (DSC) thermogram containing an endotherm in the range of about 180-190° C.; (d) a differential scanning calorimetry (DSC) thermogram comprising an endotherm with an onset of about 184° C. and a peak at about 187° C.; (e) A differential scanning calorimetry (DSC) thermogram substantially the same as that shown in FIG. (f) a thermogravimetric analysis (TGA) thermogram substantially the same as that shown in FIG. (g) XRPD unchanged after storage for 6 months at 40° C. and 75% relative humidity (RH); (h) an XRPD that remains unchanged after storage for 6 months at 25° C. and 60% relative humidity (RH); or (i) combinations thereof; 2. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide according to claim 1, or a pharma- ceutically acceptable solvate or hydrate thereof.
3. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, of claim 2, wherein crystalline Form I is characterized by an X-ray powder diffraction pattern comprising peaks at 8.7±0.2°2-θ, 21.6±0.2°2-θ, and 24.4±0.2°2-θ, or an X-ray powder diffraction pattern substantially the same as that shown in Figure 1, as measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å.
4. Crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, as described in claim 2 or claim 3, wherein crystalline form I is characterized by a differential scanning calorimetry (DSC) thermogram including an endotherm in the range of about 180 to 190°C.
5. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, according to any one of claims 2 to 4, wherein crystalline Form I is characterized by a differential scanning calorimetry (DSC) thermogram comprising an endotherm having an onset of about 184°C and a peak at about 187°C, or a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in Figure 2.
6. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, according to any one of claims 2 to 5, wherein crystalline Form I is characterized by a thermogravimetric analysis (TGA) thermogram substantially the same as that shown in Figure 3.
7. The crystalline form is crystalline form II, wherein crystalline form II is (a) an X-ray powder diffraction pattern containing peaks at 11.8±0.2° 2-θ, 8.6±0.2° 2-θ, and 15.1±0.2° 2-θ, as measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å; (b) an X-ray powder diffraction pattern substantially the same as that shown in FIG. (c) i) an endotherm in the range of about 135-145° C.; ii) an exotherm in the range of about 143-153°C; iii) an endotherm in the range of 155 to 165°C; A differential scanning calorimetry (DSC) thermogram comprising: (d) i) an endotherm having an onset of about 138° C. and a peak at about 143° C.; ii) an exotherm having an onset of about 146° C. and a peak of about 148° C.; iii) an endotherm with an onset of about 158° C. and a peak of about 160° C. A differential scanning calorimetry (DSC) thermogram comprising: (e) A differential scanning calorimetry (DSC) thermogram substantially the same as that shown in FIG. or (f) combinations thereof; 2. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide according to claim 1, or a pharma- ceutically acceptable solvate or hydrate thereof.
8. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, of claim 7, wherein crystalline Form II is characterized by an X-ray powder diffraction pattern comprising peaks at 11.8±0.2°2-θ, 8.6±0.2°2-θ, and 15.1±0.2°2-θ, or an X-ray powder diffraction pattern substantially the same as that shown in FIG. 4, as measured by X-ray powder diffraction using an X-ray wavelength of 1.5406 Å.
9. Crystal form II is i) an endotherm in the range of about 135-145° C.; ii) an exotherm in the range of about 143-153°C; iii) an endotherm in the range of 155 to 165°C; 9. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, of claim 7 or claim 8, characterized by a differential scanning calorimetry (DSC) thermogram comprising:
10. Crystalline form II is i) an endotherm with an onset of about 138° C. and a peak at about 143° C.; ii) an exotherm having an onset of about 146° C. and a peak of about 148° C.; iii) an endotherm with an onset of about 158° C. and a peak of about 160° C. or a differential scanning calorimetry (DSC) thermogram substantially the same as that shown in FIG.
5. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide of any one of claims 7 to 9, or a pharma- ceutically acceptable solvate or hydrate thereof, characterized by a differential scanning calorimetry (DSC) thermogram comprising:
11. A pharmaceutical composition comprising the crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide according to any one of claims 1 to 10, or a pharma- ceutically acceptable solvate or hydrate thereof, and at least one pharma- ceutically acceptable excipient.
12. Crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, according to any one of claims 1 to 10, for use in treating a neoplasm in a subject in need thereof.
13. The pharmaceutical composition of claim 11 for use in treating a neoplasm in a subject in need of such treatment.
14. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, of claim 12, wherein the neoplasm is cancer.
15. The pharmaceutical composition described in claim 13, wherein the neoplasm is cancer.
16. The cancer is selected from the group consisting of colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma, angiosarcoma, endothelioma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovial tumor, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, thyroid cancer, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatic cancer, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, medulloblastoma, 15. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharmaceutically acceptable solvate or hydrate thereof, of claim 14, which is a leukemia, acute lymphocytic leukemia, and acute myeloid leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia), chronic leukemia (chronic myelogenous (granulocytic) leukemia and chronic lymphocytic leukemia), as well as polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, or heavy chain disease.
17. The cancer is selected from the group consisting of colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, thyroid cancer, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chondroma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovial tumor, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, thyroid cancer, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, liver cancer, bile duct cancer, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung cancer, small cell lung cancer, non-small cell lung cancer, bladder cancer, epithelial carcinoma, glioma, star 16. The pharmaceutical composition of claim 15, wherein the cancer is selected from the group consisting of myeloma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), leukemia, acute lymphocytic leukemia, and acute myeloid leukemia (myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia), chronic leukemia (chronic myelogenous (granulocytic) leukemia and chronic lymphocytic leukemia), as well as polycythemia vera, lymphoma (Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, or heavy chain disease.
18. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, of claim 14 or claim 16, wherein the cancer is melanoma, non-small cell lung cancer, colon cancer, thyroid cancer, or ovarian cancer.
19. The pharmaceutical composition of claim 15 or claim 17, wherein the cancer is melanoma, non-small cell lung cancer, colon cancer, thyroid cancer, or ovarian cancer.
20. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, of claim 12, wherein the neoplasm is a benign tumor.
21. The pharmaceutical composition of claim 13, wherein the neoplasm is a benign tumor.
22. The crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, or a pharma- ceutically acceptable solvate or hydrate thereof, of claim 20, wherein the benign tumor is a craniopharyngioma.
23. The pharmaceutical composition described in claim 21, wherein the benign tumor is a craniopharyngioma.
24. A method for preparing crystalline form I of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, comprising the steps of: (a) dissolving N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide in a solvent to obtain a solution; (b) crystallizing the solution obtained in step (a) to obtain crystalline Form I of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide. Including, wherein crystalline Form I of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide is characterized by a powder X-ray diffraction pattern comprising peaks at 8.7±0.2° 2-θ, 21.6±0.2° 2-θ, and 24.4±0.2° 2-θ, as measured by powder X-ray diffraction using an X-ray wavelength of 1.5406 Å.
25. The method of claim 25, wherein the solvent in step (a) comprises ethyl acetate, DCM, ethanol, or isopropanol, preferably ethyl acetate; Step (a) is carried out at a temperature of about 60-90° C., preferably at a temperature of about 75-80° C.; Step (a) is carried out for about 1 to 3 hours; step (b) comprises cooling the solution obtained in step (a) to a temperature of about 20-25° C.; and optionally, the method further comprising: filtering the crystallization solution obtained in step (b) to obtain crystalline Form I of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide; drying the obtained crystalline form I; 25. The method of claim 24, further comprising:
26. A method for preparing crystalline form II of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, the method comprising: (a) dissolving N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide in a solvent to obtain a first solution; (b) adding water to the first solution obtained in step (a) to form a mixture; (c) separating the mixture obtained in step (b) into an organic phase and an aqueous phase; (d) isolating solids from the organic phase; (e) dissolving the solid obtained in step (d) in a second solvent to obtain a second solution; (f) crystallizing the second solution obtained in step (e) to obtain crystalline Form II of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide. Including, 2. A method, comprising the steps of: providing a crystalline form II of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide having a crystal ...
27. The method of claim 27, wherein the solvent in step (a) comprises ethyl acetate, DCM, ethanol, or isopropanol; the amount of water added in step (b) is such that the weight ratio of water to the solvent added in step (a) is about 1:1 to 1:10, preferably the weight ratio of water to the solvent added in step (a) is about 1:2 to 1:4; Step (d) comprises concentrating the organic phase, preferably under vacuum at a temperature of about 40-50° C.; the second solvent of step (e) comprises ethyl acetate, DCM, ethanol, or isopropanol, preferably ethyl acetate; step (f) comprises cooling the second solution obtained in step (e) to a temperature of about 10-20° C., preferably the solution is maintained at a temperature of about 10-20° C. for about 3-5 hours; and optionally, the method further comprising: filtering the crystallization solution obtained in step (f) to obtain crystalline Form II of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide; drying the obtained crystalline form II; 27. The method of claim 26, further comprising:
